Prestige Consumer Healthcare (PBH) 10-Q 4 Nov 21 2022 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Sep. 30, 2021	Oct. 29, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	001-32433
Entity Registrant Name	PRESTIGE CONSUMER HEALTHCARE INC.
Entity Central Index Key	0001295947
Current Fiscal Year End Date	--03-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-1297589
Entity Address, Address Line One	660 White Plains Road
Entity Address, City or Town	Tarrytown
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10591
City Area Code	914
Local Phone Number	524-6800
Title of 12(b) Security	Common stock, par value $0.01 per share
Trading Symbol	PBH
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		50,104,161

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenues
Total revenues	$ 276,225	$ 237,422	$ 545,406	$ 466,816
Cost of Sales
Cost of sales excluding depreciation	116,722	98,239	225,057	192,363
Cost of sales depreciation	1,791	1,522	3,625	2,924
Cost of sales	118,513	99,761	228,682	195,287
Gross profit	157,712	137,661	316,724	271,529
Operating Expenses
Advertising and marketing	40,730	38,341	80,169	66,091
General and administrative	32,252	20,388	54,723	40,322
Depreciation and amortization	6,172	6,029	11,932	12,094
Total operating expenses	79,154	64,758	146,824	118,507
Operating income	78,558	72,903	169,900	153,022
Other expense (income)
Interest expense, net	16,313	21,266	31,390	43,207
Loss on extinguishment of debt	2,122	0	2,122	0
Other expense (income), net	493	(259)	388	(249)
Total other expense, net	18,928	21,007	33,900	42,958
Income before income taxes	59,630	51,896	136,000	110,064
Provision for income taxes	14,305	7,307	32,920	21,769
Net income	$ 45,325	$ 44,589	$ 103,080	$ 88,295
Earnings per share:
Basic (in USD per share)	$ 0.90	$ 0.89	$ 2.05	$ 1.76
Diluted (in USD per share)	$ 0.89	$ 0.88	$ 2.03	$ 1.74
Weighted average shares outstanding:
Basic (in shares)	50,232	50,330	50,186	50,297
Diluted (in shares)	50,791	50,661	50,731	50,672
Comprehensive income, net of tax:
Currency translation adjustments	$ (4,197)	$ 3,665	$ (5,689)	$ 14,255
Unrealized gain on interest rate swaps	550	985	1,070	1,294
Total other comprehensive (loss) income	(3,647)	4,650	(4,619)	15,549
Comprehensive income	41,678	49,239	98,461	103,844
Net sales
Revenues
Total revenues	276,217	237,409	545,389	466,793
Other revenues
Revenues
Total revenues	$ 8	$ 13	$ 17	$ 23

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2021	Mar. 31, 2021
Current assets
Cash and cash equivalents	$ 42,818	$ 32,302
Accounts receivable, net of allowance of $18,919 and $16,457, respectively	146,553	114,671
Inventories	107,918	114,959
Prepaid expenses and other current assets	7,521	7,903
Total current assets	304,810	269,835
Property, plant and equipment, net	70,021	70,059
Operating lease right-of-use assets	22,005	23,722
Finance lease right-of-use assets, net	7,702	8,986
Goodwill	578,797	578,079
Intangible assets, net	2,689,920	2,475,729
Other long-term assets	2,563	2,863
Total Assets	3,675,818	3,429,273
Current liabilities
Current portion of long-term debt	6,000	0
Accounts payable	38,047	45,978
Accrued interest payable	17,531	6,312
Operating lease liabilities, current portion	6,085	5,858
Finance lease liabilities, current portion	2,627	2,588
Other accrued liabilities	78,650	61,402
Total current liabilities	148,940	122,138
Long-term debt, net	1,592,981	1,479,653
Deferred income tax liabilities	440,275	434,050
Long-term operating lease liabilities, net of current portion	17,993	19,706
Long-term finance lease liabilities, net of current portion	5,493	6,816
Other long-term liabilities	8,489	8,612
Total Liabilities	2,214,171	2,070,975
Commitments and Contingencies — Note 17
Stockholders' Equity
Preferred stock - $0.01 par value; Authorized - 5,000 shares; Issued and outstanding - None	0	0
Common stock - $0.01 par value; Authorized - 250,000 shares; Issued - 54,211 shares at June 30, 2021 and 53,999 shares at March 31, 2021	542	540
Additional paid-in capital	507,310	499,508
Treasury stock, at cost - 4,151 shares at September 30, 2021 and 4,088 shares at March 31, 2021	(133,648)	(130,732)
Accumulated other comprehensive loss, net of tax	(24,420)	(19,801)
Retained earnings	1,111,863	1,008,783
Total Stockholders' Equity	1,461,647	1,358,298
Total Liabilities and Stockholders' Equity	$ 3,675,818	$ 3,429,273

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2021	Mar. 31, 2021
Statement of Financial Position [Abstract]
Allowance for doubtful accounts receivable, current	$ 18,919	$ 16,457
Stockholders' Equity:
Preferred stock, par value (in USD per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in USD per share)	$ 0.01	$ 0.01
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	54,247,000	53,999,000
Treasury stock (in shares)	4,151,000	4,088,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Other Comprehensive Income (Loss)	Retained Earnings
Common stock, beginning balance (in shares) at Mar. 31, 2020		53,805,000
Equity, beginning balance at Mar. 31, 2020	$ 1,170,971	$ 538	$ 488,116	$ (117,623)	$ (44,161)	$ 844,101
Treasury stock, beginning balance (in shares) at Mar. 31, 2020				3,719,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	$ 4,356		4,356
Exercise of stock options (in shares)	62,800	62,000
Exercise of stock options	$ 1,285		1,285
Issuance of shares related to restricted stock		74,000
Issuance of shares related to restricted stock	0	$ 1	(1)
Treasury share repurchases				60,000
Treasury share repurchases	(2,239)			$ (2,239)
Net income	88,295					88,295
Comprehensive income (loss)	15,549				15,549
Common stock, ending balance (in shares) at Sep. 30, 2020		53,941,000
Equity, ending balance at Sep. 30, 2020	1,278,217	$ 539	493,756	$ (119,862)	(28,612)	932,396
Treasury stock, ending balance (in shares) at Sep. 30, 2020				3,779,000
Common stock, beginning balance (in shares) at Jun. 30, 2020		53,939,000
Equity, beginning balance at Jun. 30, 2020	1,227,014	$ 539	490,795	$ (118,865)	(33,262)	887,807
Treasury stock, beginning balance (in shares) at Jun. 30, 2020				3,750,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	2,892		2,892
Exercise of stock options (in shares)		2,000
Exercise of stock options	69		69
Treasury share repurchases				29,000
Treasury share repurchases	(997)			$ (997)
Net income	44,589					44,589
Comprehensive income (loss)	4,650				4,650
Common stock, ending balance (in shares) at Sep. 30, 2020		53,941,000
Equity, ending balance at Sep. 30, 2020	1,278,217	$ 539	493,756	$ (119,862)	(28,612)	932,396
Treasury stock, ending balance (in shares) at Sep. 30, 2020				3,779,000
Common stock, beginning balance (in shares) at Mar. 31, 2021		53,999,000
Equity, beginning balance at Mar. 31, 2021	$ 1,358,298	$ 540	499,508	$ (130,732)	(19,801)	1,008,783
Treasury stock, beginning balance (in shares) at Mar. 31, 2021	4,088,000			4,088,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	$ 5,097		5,097
Exercise of stock options (in shares)	87,600	88,000
Exercise of stock options	$ 2,707		2,707
Issuance of shares related to restricted stock		160,000
Issuance of shares related to restricted stock	0	$ 2	(2)
Treasury share repurchases				63,000
Treasury share repurchases	(2,916)			$ (2,916)
Net income	103,080					103,080
Comprehensive income (loss)	(4,619)				(4,619)
Common stock, ending balance (in shares) at Sep. 30, 2021		54,247,000
Equity, ending balance at Sep. 30, 2021	$ 1,461,647	$ 542	507,310	$ (133,648)	(24,420)	1,111,863
Treasury stock, ending balance (in shares) at Sep. 30, 2021	4,151,000			4,151,000
Common stock, beginning balance (in shares) at Jun. 30, 2021		54,211,000
Equity, beginning balance at Jun. 30, 2021	$ 1,416,247	$ 542	503,588	$ (133,648)	(20,773)	1,066,538
Treasury stock, beginning balance (in shares) at Jun. 30, 2021				4,151,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	3,219		3,219
Exercise of stock options (in shares)		20,000
Exercise of stock options	503		503
Issuance of shares related to restricted stock		16,000
Net income	45,325					45,325
Comprehensive income (loss)	(3,647)				(3,647)
Common stock, ending balance (in shares) at Sep. 30, 2021		54,247,000
Equity, ending balance at Sep. 30, 2021	$ 1,461,647	$ 542	$ 507,310	$ (133,648)	$ (24,420)	$ 1,111,863
Treasury stock, ending balance (in shares) at Sep. 30, 2021	4,151,000			4,151,000

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Operating Activities
Net income	$ 103,080	$ 88,295
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	15,557	15,018
Loss on disposal of property and equipment	27	131
Deferred income taxes	7,639	3,656
Amortization of debt origination costs	1,435	2,918
Stock-based compensation costs	5,097	4,356
Loss on extinguishment of debt	2,122	0
Non-cash operating lease cost	3,351	3,587
Other	0	109
Changes in operating assets and liabilities, net of effects from acquisition:
Accounts receivable	(34,322)	29,358
Inventories	12,978	3,213
Prepaid expenses and other current assets	473	(2,476)
Accounts payable	(8,275)	(9,183)
Accrued liabilities	24,570	(8,125)
Operating lease liabilities	(3,150)	(3,446)
Other	(83)	(118)
Net cash provided by operating activities	130,499	127,293
Investing Activities
Purchases of property, plant and equipment	(4,252)	(11,619)
Acquisition of Akorn	(228,914)	0
Other	177	0
Net cash used in investing activities	(232,989)	(11,619)
Financing Activities
Term loan repayments	(495,000)	(130,000)
Proceeds from refinancing of Term Loan	597,000	0
Borrowings under revolving credit agreement	85,000	0
Repayments under revolving credit agreement	(65,000)	(55,000)
Payments of debt costs	(6,111)	0
Payments of finance leases	(1,496)	(712)
Proceeds from exercise of stock options	2,707	1,285
Fair value of shares surrendered as payment of tax withholding	(2,916)	(1,242)
Repurchase of common stock	0	(997)
Net cash provided by (used in) financing activities	114,184	(186,666)
Effects of exchange rate changes on cash and cash equivalents	(1,178)	2,835
Increase (decrease) in cash and cash equivalents	10,516	(68,157)
Cash and cash equivalents - beginning of period	32,302	94,760
Cash and cash equivalents - end of period	42,818	26,603
Supplemental Cash Flow Information [Abstract]
Interest paid	18,481	42,423
Income taxes paid	$ 21,141	$ 18,818

Business and Basis of Presentat

Business and Basis of Presentation	6 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business and Basis of Presentation	Business and Basis of Presentation Nature of Business Prestige Consumer Healthcare Inc. (referred to herein as the “Company” or “we,” which reference shall, unless the context requires otherwise, be deemed to refer to Prestige Consumer Healthcare Inc. and all of its direct and indirect 100% owned subsidiaries on a consolidated basis) is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (“OTC”) healthcare products to mass merchandisers, drug, food, dollar, convenience and club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. Prestige Consumer Healthcare Inc. is a holding company with no operations and is also the parent guarantor of the senior credit facility and the senior notes described in Note 8 to these Condensed Consolidated Financial Statements. Economic Environment Since the Coronavirus Outbreak In March 2020, the World Health Organization ("WHO") declared a global pandemic due to a new strain of coronavirus ("COVID-19"). The pandemic has caused significant volatility in the United States and global economies. We expect economic conditions will continue to be highly volatile and uncertain and could affect demand for our products and put pressure on prices. We experienced a temporary but significant decline in consumer consumption of our brands in the first quarter of fiscal 2021, followed by more stable consumption and customer orders over the remainder of the year. Generally, throughout the pandemic some categories were positively impacted (for instance, Women’s Health, Oral Care and Dermatological) and some categories negatively impacted (for instance, Cough & Cold and Gastrointestinal). The positively impacted categories benefited from the consumer shift to over-the-counter healthcare products as consumers increased their focus on hygiene and self-care at home related to COVID-19. The declining categories were impacted by reduced incidence levels and usage rates due to shelter-at-home restrictions and limited travel-related activity. In the first half of fiscal 2022, we experienced solid consumer consumption and share gains across most of our brand portfolio. Our business also benefited from a significant increase in demand in certain travel-related categories and channels and, to a lesser extent, the Cough & Cold category, previously impacted by the COVID-19 virus. We have continued to see changes in the purchasing patterns of our consumers, including the frequency of visits by consumers to retailers and a shift in many markets to purchasing our products online. Although we have not experienced a material disruption to our overall supply chain to date, we may experience delays and backorders for certain ingredients and products, difficulty scheduling shipping for our products, as well as price increases from certain of our suppliers for both shipping and product costs. In addition, labor shortages have begun to impact our manufacturing operations and may impact our ability to supply certain products to our customers. To date, the pandemic has not had a material negative impact on our operations, supply chain, overall demand for most of our products or resulting aggregate sales and earnings, and, as such, it has also not negatively impacted our liquidity position. We continue to generate operating cash flows to meet our short-term liquidity needs. These circumstances could change, however, in this dynamic, unprecedented environment. If the outbreak continues to spread or labor shortage issues otherwise worsen, it may materially affect our operations and those of third parties on which we rely, including causing disruptions in the supply and distribution of our products. We may need to limit operations and may experience material limitations in employee and other labor resources. The extent to which COVID-19 and related economic conditions impact our results and liquidity will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19, and the actions to contain COVID-19 or treat its impact, among others. These effects could have a material, adverse impact on our business, liquidity, capital resources, and results of operations and those of the third parties on which we rely. Basis of Presentation The unaudited Condensed Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. All significant intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, these Condensed Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented. Our fiscal year ends on March 31 st of each year. References in these Condensed Consolidated Financial Statements or related notes to a year (e.g., 2022) mean our fiscal year ending or ended on March 31 st of that year. Operating results for the six months ended September 30, 2021 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2022. These unaudited Condensed Consolidated Financial Statements and related notes should be read in conjunction with our audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2021. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ from those estimates. Our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances, inventory obsolescence, and accounting for income taxes and related uncertain tax positions. Recently Adopted Accounting Pronouncements In December 2019, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes . The amendments in this update eliminate the need for an organization to analyze whether certain exceptions apply for tax purposes. It also simplifies GAAP for certain taxes. The amendments in these updates are effective for us for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. We adopted this standard effective April 1, 2021, and the adoption of this standard did not have a material impact on our Consolidated Financial Statements. Recently Issued Accounting Pronouncements In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting . This ASU provides optional expedient and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. In response to the concerns about structural risks of interbank offered rates (“IBORs”) and, particularly, the risk of cessation of the London Interbank Offered Rate (“LIBOR”), regulators in several jurisdictions around the world have undertaken reference rate reform initiatives to identify alternative reference rates that are more observable or transaction based and less susceptible to manipulation. The ASU provides companies with optional guidance to ease the potential accounting burden associated with transitioning away from reference rates that are expected to be discontinued. In January 2021, the FASB issued ASU 2021-01, which adds implementation guidance to clarify certain optional expedients in Topic 848. The ASUs can be adopted no later than December 31, 2022 with early adoption permitted. We are currently evaluating the effect of adopting this new accounting guidance.

Acquisition

Acquisition	6 Months Ended
	Sep. 30, 2021
Business Combinations [Abstract]
Acquisition	Acquisition On July 1, 2021, we completed the acquisition of the consumer health business assets from Akorn Operating Company LLC ("Akorn") pursuant to an Asset Purchase Agreement, dated May 27, 2021 (the "Purchase Agreement"), for a purchase price of $228.9 million in cash, subject to certain closing adjustments specified in the Purchase Agreement. As a result of the purchase, we acquired TheraTears and certain other over-the-counter consumer brands. The financial results from this acquisition are included in our North American OTC Healthcare segment. The purchase price was funded by a combination of available cash on hand, additional borrowings under the 2012 ABL Revolver and the net proceeds from the refinancing of our term loan entered into on January 31, 2012 (the "2012 Term Loan") (see Note 8). The acquisition was accounted for as a business combination. During the three months ended September 30, 2021, we incurred acquisition-related costs of $5.1 million which are included in General and administrative expense. In connection with the acquisition, we also entered into a supply arrangement with Akorn for a term of three years with optional renewals at prevailing market rates. We prepared an analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. These purchase price allocations are preliminary as we are in the process of finalizing the valuation. The following table summarizes our preliminary allocation of the assets acquired and liabilities assumed as of the July 1, 2021 acquisition date. (In thousands) July 1, 2021 Inventories $ 6,432 Goodwill 1,758 Intangible assets 228,970 Total assets acquired 237,160 Accounts payable 591 Reserves for sales allowances and cash discounts 2,227 Other accrued liabilities 5,428 Total liabilities assumed 8,246 Total purchase price $ 228,914 Based on this preliminary analysis, we allocated $204.1 million to non-amortizable intangible assets and $24.9 million to amortizable intangible assets. The non-amortizable intangible assets are classified as trademarks and, of the amortizable intangible assets, $19.6 million are classified as customer relationships and $5.3 million are classified as trademarks. We are amortizing the purchased amortizable intangible assets on a straight-line basis over an estimated weighted average useful life of 12.5 years (see Note 5). We recorded goodwill of $1.8 million based on the amount by which the purchase price exceeded the preliminary estimate of the fair value of the net assets acquired (see Note 4). Goodwill is deductible and is being amortized for income tax purposes.

Inventories

Inventories	6 Months Ended
	Sep. 30, 2021
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consist of the following: (In thousands) September 30, 2021 March 31, 2021 Components of Inventories Packaging and raw materials $ 11,333 $ 8,463 Work in process 344 326 Finished goods 96,241 106,170 Inventories $ 107,918 $ 114,959

Goodwill

Goodwill	6 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Goodwill A reconciliation of the activity affecting goodwill by operating segment is as follows: (In thousands) North American OTC International OTC Consolidated Balance - March 31, 2021 Goodwill $ 710,354 $ 32,683 $ 743,037 Accumulated impairment loss (163,711) (1,247) (164,958) Balance - March 31, 2021 546,643 31,436 578,079 2022 Additions 1,758 — 1,758 Effects of foreign currency exchange rates — (1,040) (1,040) Balance - September 30, 2021 Goodwill 712,112 31,643 743,755 Accumulated impairment loss (163,711) (1,247) (164,958) Balance - September 30, 2021 $ 548,401 $ 30,396 $ 578,797 As discussed in Note 2, on July 1, 2021, we completed the acquisition of Akorn. In connection with this acquisition, we recorded goodwill of $1.8 million based on the amount by which the purchase price exceeded the preliminary estimate of the fair value of the net assets acquired. On an annual basis during the fourth quarter of each fiscal year, or more frequently if conditions indicate that the carrying value of the asset may not be recoverable, management performs a review of the values assigned to goodwill and tests for impairment. We utilize the discounted cash flow method to estimate the fair value of our reporting units as part of the goodwill impairment test. We also considered our market capitalization at February 28, 2021, which was the date of our annual review, as compared to the aggregate fair values of our reporting units, to assess the reasonableness of our estimates pursuant to the discounted cash flow methodology. The estimates and assumptions made in assessing the fair value of our reporting units and the valuation of the underlying assets and liabilities are inherently subject to significant uncertainties related to future sales, gross margins, and advertising and marketing expenses, which can be impacted by increases in competition, changing consumer preferences, technical advances, or the potential impacts of COVID-19. The discount rate assumption may be influenced by such factors as changes in interest rates and rates of inflation, which can have an impact on the determination of fair value. If these assumptions are adversely affected, we may be required to record impairment charges in the future. We continuously monitor events that could trigger an interim impairment analysis, which included the impact of COVID-19 for the period ended September 30, 2021.

Intangible Assets, net

Intangible Assets, net	6 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, net	Intangible Assets, net A reconciliation of the activity affecting intangible assets, net is as follows: (In thousands) Indefinite- Finite-Lived Totals Gross Carrying Amounts Balance — March 31, 2021 $ 2,281,988 $ 389,347 $ 2,671,335 Additions 204,100 24,870 228,970 Effects of foreign currency exchange rates (4,498) (139) (4,637) Balance — September 30, 2021 2,481,590 414,078 2,895,668 Accumulated Amortization Balance — March 31, 2021 — 195,606 195,606 Additions — 10,228 10,228 Effects of foreign currency exchange rates — (86) (86) Balance — September 30, 2021 — 205,748 205,748 Intangible assets, net - September 30, 2021 $ 2,481,590 $ 208,330 $ 2,689,920 Amortization expense was $5.3 million and $10.2 million for the three and six months ended September 30, 2021, respectively, and $4.9 million and $9.8 million for the three and six months ended September 30, 2020, respectively. As discussed in Note 2, on July 1, 2021, we completed the acquisition of Akorn. In connection with this acquisition, we allocated $229.0 million to intangible assets based on our preliminary analysis. Finite-lived intangible assets are expected to be amortized over their estimated useful life, which ranges from a period of 10 to 30 years, and the estimated amortization expense for each of the five succeeding years and the periods thereafter is as follows (in thousands): (In thousands) Year Ending March 31, Amount 2022 (remaining six months ended March 31, 2022) $ 10,721 2023 21,413 2024 21,379 2025 19,287 2026 16,904 Thereafter 118,626 $ 208,330 Under accounting guidelines, indefinite-lived assets are not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the asset below the carrying amount. On February 28, 2021, the date of our annual impairment review, there were no indicators of impairment as a result of the analysis and, accordingly, no additional impairment charge was taken on our March 31, 2021 financial statements. Additionally, at each reporting period, an evaluation must be made to determine whether events and circumstances continue to support an indefinite useful life. Intangible assets with finite lives are amortized over their respective estimated useful lives and are also tested for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable and exceeds its fair value. We utilize the excess earnings method to estimate the fair value of our individual indefinite-lived intangible assets. The assumptions subject to significant uncertainties include the discount rate utilized in the analyses, as well as future sales, gross margins, and advertising and marketing expenses. The discount rate assumption may be influenced by such factors as changes in interest rates and rates of inflation, which can have an impact on the determination of fair value. Additionally, should the related fair values of intangible assets be adversely affected as a result of declining sales or margins caused by competition, changing consumer needs or preferences, technological advances, changes in advertising and marketing expenses, or the potential impacts of COVID-19, we may be required to record impairment charges in the future. As of September 30, 2021, no events have occurred that would indicate potential impairment of intangible assets.

Leases

Leases	6 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Leases	Leases We lease real estate and equipment for use in our operations. The components of lease expense for the three and six months ended September 30, 2021 and 2020 were as follows: Three Months Ended September 30, Six Months Ended September 30, (In thousands) 2021 2020 2021 2020 Finance lease cost: Amortization of right-of-use assets $ 642 $ 443 $ 1,284 $ 768 Interest on lease liabilities 63 59 129 109 Operating lease cost 1,683 1,692 3,370 3,389 Short term lease cost 24 22 46 45 Variable lease cost 11,998 12,303 23,649 24,010 Sublease income — (55) — (109) Total net lease cost $ 14,410 $ 14,464 $ 28,478 $ 28,212 As of September 30, 2021, the maturities of lease liabilities were as follows: (In thousands) Year Ending March 31, Operating Leases Finance Total 2022 (Remaining six months ending March 31, 2022) $ 3,673 $ 1,413 $ 5,086 2023 6,211 2,826 9,037 2024 6,416 2,826 9,242 2025 4,220 1,412 5,632 2026 1,898 — 1,898 Thereafter 3,608 — 3,608 Total undiscounted lease payments 26,026 8,477 34,503 Less amount of lease payments representing interest (1,948) (357) (2,305) Total present value of lease payments $ 24,078 $ 8,120 $ 32,198 The weighted average remaining lease term and weighted average discount rate were as follows: September 30, 2021 Weighted average remaining lease term (years) Operating leases 4.41 Finance leases 3.00 Weighted average discount rate Operating leases 3.00 % Finance leases 2.98 %
Leases	Leases We lease real estate and equipment for use in our operations. The components of lease expense for the three and six months ended September 30, 2021 and 2020 were as follows: Three Months Ended September 30, Six Months Ended September 30, (In thousands) 2021 2020 2021 2020 Finance lease cost: Amortization of right-of-use assets $ 642 $ 443 $ 1,284 $ 768 Interest on lease liabilities 63 59 129 109 Operating lease cost 1,683 1,692 3,370 3,389 Short term lease cost 24 22 46 45 Variable lease cost 11,998 12,303 23,649 24,010 Sublease income — (55) — (109) Total net lease cost $ 14,410 $ 14,464 $ 28,478 $ 28,212 As of September 30, 2021, the maturities of lease liabilities were as follows: (In thousands) Year Ending March 31, Operating Leases Finance Total 2022 (Remaining six months ending March 31, 2022) $ 3,673 $ 1,413 $ 5,086 2023 6,211 2,826 9,037 2024 6,416 2,826 9,242 2025 4,220 1,412 5,632 2026 1,898 — 1,898 Thereafter 3,608 — 3,608 Total undiscounted lease payments 26,026 8,477 34,503 Less amount of lease payments representing interest (1,948) (357) (2,305) Total present value of lease payments $ 24,078 $ 8,120 $ 32,198 The weighted average remaining lease term and weighted average discount rate were as follows: September 30, 2021 Weighted average remaining lease term (years) Operating leases 4.41 Finance leases 3.00 Weighted average discount rate Operating leases 3.00 % Finance leases 2.98 %

Other Accrued Liabilities

Other Accrued Liabilities	6 Months Ended
	Sep. 30, 2021
Payables and Accruals [Abstract]
Other Accrued Liabilities	Other Accrued Liabilities Other accrued liabilities consist of the following: (In thousands) September 30, 2021 March 31, 2021 Accrued marketing costs $ 44,603 $ 29,955 Accrued compensation costs 11,638 14,074 Accrued broker commissions 943 1,023 Income taxes payable 1,551 1,652 Accrued professional fees 4,743 4,472 Accrued production costs 3,790 2,882 Accrued sales tax 977 2,368 Other accrued liabilities 10,405 4,976 $ 78,650 $ 61,402

Long-Term Debt

Long-Term Debt	6 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Long-Term Debt	Long-Term Debt Long-term debt consists of the following, as of the dates indicated: (In thousands, except percentages) September 30, 2021 March 31, 2021 2021 Senior Notes bearing interest at 3.750%, with interest payable on April 1 and October 1 of each year. The 2021 Senior Notes mature on April 1, 2031. $ 600,000 $ 600,000 2019 Senior Notes bearing interest at 5.125%, with interest payable on January 15 and July 15 of each year. The 2019 Senior Notes mature on January 15, 2028. 400,000 400,000 2012 Term B-5 Loans bearing interest at the Borrower's option at either LIBOR plus a margin of 2.00%, with a LIBOR floor of 0.00%, or an alternate base rate plus a margin of 1.00% per annum, with a base rate floor of 1.00%, due on January 24, 2024. — 495,000 2012 Term B-5 Loans bearing interest at the Borrower's option at either LIBOR plus a margin of 2.00%, with a LIBOR floor of 0.50%, or an alternate base rate plus a margin of 1.00% per annum, due on July 1, 2028. 600,000 — 2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on December 11, 2024. 20,000 — Total long-term debt (including current portion) 1,620,000 1,495,000 Current portion of long-term debt 6,000 — Long-term debt 1,614,000 1,495,000 Less: unamortized debt costs (21,019) (15,347) Long-term debt, net $ 1,592,981 $ 1,479,653 At September 30, 2021, we had $20.0 million outstanding on the asset-based revolving credit facility entered into January 31, 2012, as amended (the "2012 ABL Revolver"), and a borrowing capacity of $104.6 million. On July 1, 2021, we entered into Amendment No. 6 ("Term Loan Amendment No. 6") to the 2012 Term Loan. Term Loan Amendment No. 6 provides for (i) the refinancing of our outstanding term loans and the creation of a new class of Term B-5 Loans under the credit agreement governing the 2012 Term Loan in an aggregate principal amount of $600.0 million, (ii) increased flexibility under the credit agreement and (iii) an interest rate on the Term B-5 Loans that is based, at the Borrower's option, on a LIBOR rate plus a margin of 2.00% per annum, with a LIBOR floor of 0.50%, or an alternative base rate plus a margin of 1.00% per annum. In addition, Term Loan Amendment No. 6 provides for an extension of the maturity date to July 1, 2028. Under Term Loan Amendment No. 6, we are required to make quarterly payments each equal to 0.25% of the aggregate principal amount. During the three months ended September 30, 2021, we recorded a loss on extinguishment of debt of $2.1 million to write off a portion of new and old debt costs relating to this refinancing. The net proceeds from the new class of Term B-5 Loans were used to refinance our outstanding term loans, finance the acquisition of Akorn and pay fees and expenses incurred in connection with these transactions (see Note 2). Interest Rate Swaps: We currently have an interest rate swap to hedge a tota l of $200.0 million of our variable interest debt (see Note 10 for further details). As of September 30, 2021, aggregate future principal payments required in accordance with the terms of the 2012 Term B-5 Loans, 2012 ABL Revolver and the indentures governing the senior unsecured notes due 2031 (the "2021 Senior Notes") and the senior unsecured notes due 2028 (the "2019 Senior Notes") are as follows: (In thousands) Year Ending March 31, Amount 2022 (remaining six months ending March 31, 2022) $ 3,000 2023 6,000 2024 6,000 2025 26,000 2026 6,000 Thereafter 1,573,000 $ 1,620,000

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements For certain of our financial instruments, including cash, accounts receivable, accounts payable and other current liabilities, the carrying amounts approximate their respective fair values due to the relatively short maturity of these amounts. FASB Accounting Standards Codification ("ASC") 820, Fair Value Measurements , requires fair value to be determined based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market assuming an orderly transaction between market participants. ASC 820 established market (observable inputs) as the preferred source of fair value, to be followed by our assumptions of fair value based on hypothetical transactions (unobservable inputs) in the absence of observable market inputs. Based upon the above, the following fair value hierarchy was created: Level 1 - Quoted market prices for identical instruments in active markets; Level 2 - Quoted prices for similar instruments in active markets, as well as quoted prices for identical or similar instruments in markets that are not considered active; and Level 3 - Unobservable inputs developed by us using estimates and assumptions reflective of those that would be utilized by a market participant. The market values have been determined based on market values for similar instruments adjusted for certain factors. As such, the 2021 Senior Notes, the 2019 Senior Notes, the 2012 Term B-5 Loans, and the 2012 ABL Revolver and our interest rate swaps are measured in Level 2 of the above hierarchy. The summary below details the carrying amounts and estimated fair values of these instruments at September 30, 2021 and March 31, 2021. September 30, 2021 March 31, 2021 (In thousands) Carrying Value Fair Value Carrying Value Fair Value 2021 Senior Notes $ 600,000 $ 577,500 $ 600,000 $ 570,000 2019 Senior Notes 400,000 416,000 400,000 417,000 2012 Term B-5 Loans, Amendment No. 5 — — 495,000 493,763 2012 Term B-5 Loans, Amendment No. 6 600,000 599,250 — — 2012 ABL Revolver 20,000 20,000 — — Interest rate swaps 973 973 2,363 2,363

Derivative Instruments

Derivative Instruments	6 Months Ended
	Sep. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments	Derivative InstrumentsChanges in interest rates expose us to risks. To help us manage these risks, in January 2020 we entered into two interest rate swaps to hedge a total of $400.0 million of our variable interest debt. One swap settled on January 31, 2021 and, as of September 30, 2021, one interest rate swap to hedge $200.0 million remained outstanding. The fair value of this interest rate swap is reflected in our Consolidated Balance Sheets in other accrued liabilities. We do not use derivatives for trading purposes. The following tables summarize the fair values of our derivative instrument as of the end of the periods shown: September 30, 2021 (In thousands) Hedge Type Final Settlement Date Notional Amount Other Accrued Liabilities Other Long-Term Liabilities Interest rate swap Cash flow 1/31/2022 $ 200,000 $ (973) $ — Total fair value $ (973) $ — March 31, 2021 (In thousands) Hedge Type Final Settlement Date Notional Amount Other Accrued Liabilities Other Long-Term Liabilities Interest rate swap Cash flow 1/31/2022 $ 200,000 $ (2,363) $ — Total fair value $ (2,363) $ — The following table summarizes our interest rate swaps, net of tax, for the periods shown: Three Months Ended September 30, Six Months Ended September 30, (In thousands) Location 2021 2020 2021 2020 Gain Recognized in Other Comprehensive Loss (effective portion) Other comprehensive income (loss) $ 550 $ 985 $ 1,070 $ 1,294 Loss Reclassified from Accumulated Other Comprehensive Loss into Income Interest expense $ (732) $ (1,396) $ (1,450) $ (2,422) We expect pre-tax losses of $1.0 million associated with interest rate swaps, currently reported in accumulated other comprehensive loss, to be reclassified into expense over the next twelve months. The amount ultimately realized, however, will differ as interest rates change and the underlying contracts settle. Counterparty Credit Risk:

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Sep. 30, 2021
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders' Equity We are authorized to issue 250.0 million shares of common stock, $0.01 par value per share, and 5.0 million shares of preferred stock, $0.01 par value per share. The Board of Directors may direct the issuance of the undesignated preferred stock in one or more series and determine preferences, privileges and restrictions thereof. Each share of common stock has the right to one vote on all matters submitted to a vote of stockholders. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to prior rights of holders of all classes of outstanding stock having priority rights as to dividends. No dividends have been declared or paid on our common stock through September 30, 2021. During the six months ended September 30, 2021 and the three and six months ended September 30, 2020, we repurchased shares of our common stock and recorded them as treasury stock. Our share repurchases consisted of the following: Three Months Ended September 30, Six Months Ended September 30, 2021 2020 2021 2020 Shares repurchased pursuant to the provisions of the various employee restricted stock awards: Number of shares — — 63,314 31,117 Average price per share $ — $ — $46.04 $39.91 Total amount repurchased $ — $ — $2.9 million $1.2 million Shares repurchased in conjunction with our share repurchase program: Number of shares — 28,865 — 28,865 Average price per share $ — $34.55 $ — $34.55 Total amount repurchased $ — $1.0 million $ — $1.0 million

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	6 Months Ended
	Sep. 30, 2021
Stockholders' Equity Note [Abstract]
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss Accumulated other comprehensive loss consisted of the following at September 30, 2021 and March 31, 2021: (In thousands) September 30, 2021 March 31, 2021 Components of Accumulated Other Comprehensive Loss Cumulative translation adjustment $ (24,597) $ (18,908) Unrealized loss on interest rate swaps, net of tax of $224 and $543, respectively (749) (1,819) Unrecognized net gain (loss) on pension plans, net of tax of $(276) and $(276), respectively 926 926 Accumulated other comprehensive loss, net of tax $ (24,420) $ (19,801)

Earnings Per Share

Earnings Per Share	6 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Basic earnings per share is computed based on income available to common stockholders and the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is computed based on income available to common stockholders and the weighted average number of shares of common stock outstanding plus the effect of potentially dilutive common shares outstanding during the period using the treasury stock method, which includes stock options, restricted stock units ("RSUs") and performance stock units ("PSUs"). Potential common shares, composed of the incremental common shares issuable upon the exercise of outstanding stock options and unvested RSUs, are included in the diluted earnings per share calculation to the extent that they are dilutive. In loss periods, the assumed exercise of in-the-money stock options and RSUs has an anti-dilutive effect, and therefore these instruments are excluded from the computation of diluted earnings per share. The following table sets forth the computation of basic and diluted earnings per share: Three Months Ended September 30, Six Months Ended September 30, (In thousands, except per share data) 2021 2020 2021 2020 Numerator Net income $ 45,325 $ 44,589 $ 103,080 $ 88,295 Denominator Denominator for basic earnings per share — weighted average shares outstanding 50,232 50,330 50,186 50,297 Dilutive effect of unvested restricted stock units and options issued to employees and directors 559 331 545 375 Denominator for diluted earnings per share 50,791 50,661 50,731 50,672 Earnings per Common Share: Basic earnings per share $ 0.90 $ 0.89 $ 2.05 $ 1.76 Diluted earnings per share $ 0.89 $ 0.88 $ 2.03 $ 1.74

Share-Based Compensation

Share-Based Compensation	6 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Share-Based Compensation	Share-Based Compensation In connection with our initial public offering, the Board of Directors adopted the 2005 Long-Term Equity Incentive Plan (the “2005 Plan”), which provided for grants of up to a maximum of 5.0 million shares of restricted stock, stock options, RSUs and other equity-based awards. In June 2014, the Board of Directors approved, and in July 2014, our stockholders ratified, an increase of an additional 1.8 million shares of our common stock for issuance under the 2005 Plan, an increase of the maximum number of shares subject to stock options that could be awarded to any one participant under the 2005 Plan during any fiscal 12-month period from 1.0 million to 2.5 million shares, and an extension of the term of the 2005 Plan by ten years, to February 2025. Directors, officers and other employees of the Company and its subsidiaries, as well as others performing services for the Company, were eligible for grants under the 2005 Plan. On June 23, 2020, the Board of Directors adopted the Prestige Consumer Healthcare Inc. 2020 Long-Term Incentive Plan (the “2020 Plan”). The 2020 Plan became effective on August 4, 2020, upon the approval of the 2020 Plan by our stockholders. On June 23, 2020, a total of 2,827,210 shares were available for issuance under the 2020 Plan (comprised of 2,000,000 new shares plus 827,210 shares that were unissued under the 2005 Plan). All future equity awards will be made from the 2020 Plan, and the Company will not grant any additional awards under the 2005 Plan. The following table provides information regarding our stock-based compensation: Three Months Ended September 30, Six Months Ended September 30, (In thousands) 2021 2020 2021 2020 Pre-tax share-based compensation costs charged against income $ 3,219 $ 2,892 $ 5,097 $ 4,356 Income tax benefit recognized on compensation costs $ 369 $ 451 $ 512 $ 563 Total fair value of options and RSUs vested during the period $ 937 $ 1,015 $ 7,943 $ 6,796 Cash received from the exercise of stock options $ 503 $ 69 $ 2,707 $ 1,285 Tax benefits realized from tax deductions resulting from RSU issuances and stock option exercises $ 350 $ 4 $ 2,071 $ 948 At September 30, 2021, there were $4.0 million of unrecognized compensation costs related to unvested stock options under the 2005 Plan and the 2020 Plan, excluding an estimate for forfeitures which may occur. We expect to recognize such costs over a weighted average period of 2.2 years. At September 30, 2021, there were $11.2 million of unrecognized compensation costs related to unvested RSUs and PSUs under the 2005 Plan and the 2020 Plan, excluding an estimate for forfeitures which may occur. We expect to recognize such costs over a weighted average period of 2.0 years. At September 30, 2021, there were 2.5 million shares available for issuance under the 2020 Plan. On May 3, 2021, the Compensation and Talent Management Committee (the "Committee") of our Board of Directors granted 77,345 PSUs, 73,108 RSUs, and stock options to acquire 222,660 shares of our common stock under the 2020 Plan to certain executive officers and employees. The stock options were granted at an exercise price of $44.33 per share, which was equal to the closing price for our common stock on the date of the grant. A newly appointed independent member of the Board of Directors received a grant under the 2020 Plan of 1,636 RSUs on May 3, 2021. Each of the independent members of the Board of Directors received a grant of 2,808 RSUs on August 3, 2021 under the 2020 Plan. The RSUs are fully vested upon receipt of the award and will be settled by delivery to each director of one share of our common stock for each vested RSU promptly following the earliest of (i) such director's death, (ii) such director's separation from service or (iii) a change in control of the Company. Restricted Stock Units The fair value of the RSUs is determined using the closing price of our common stock on the date of the grant. A summary of the RSUs granted under the 2005 Plan and the 2020 Plan is presented below: RSUs Shares (in thousands) Weighted Six Months Ended September 30, 2020 Unvested at March 31, 2020 387.9 $ 33.11 Granted 179.7 40.22 Vested (100.2) 42.94 Forfeited (4.7) 56.11 Unvested at September 30, 2020 462.7 33.51 Vested at September 30, 2020 150.4 31.98 Six Months Ended September 30, 2021 Unvested at March 31, 2021 457.0 $ 33.52 Granted 170.8 45.32 Vested (162.3) 32.99 Forfeited (24.6) 30.54 Unvested at September 30, 2021 440.9 38.45 Vested at September 30, 2021 152.3 33.92 Options The fair value of each award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions presented below: Six Months Ended September 30, 2021 2020 Expected volatility 31.1% - 31.9% 32.1% - 32.2% Expected dividends $ — $ — Expected term in years 6.0 to 7.0 6.0 to 7.0 Risk-free rate 1.0% to 1.3% 0.5% Weighted average grant date fair value of options granted $ 14.87 $ 12.91 A summary of option activity under the 2005 Plan and the 2020 Plan is as follows: Options Shares (in thousands) Weighted Weighted Aggregate Six Months Ended September 30, 2020 Outstanding at March 31, 2020 1,020.2 $ 35.90 Granted 249.9 39.98 Exercised (62.8) 20.46 Forfeited — — Expired — — Outstanding at September 30, 2020 1,207.3 37.55 7.0 $ 5,032 Vested at September 30, 2020 699.1 39.39 5.6 $ 3,430 Six Months Ended September 30, 2021 Outstanding at March 31, 2021 1,114.9 $ 37.92 Granted 234.2 44.74 Exercised (87.6) 30.91 Forfeited (13.7) 37.83 Expired (8.5) 56.63 Outstanding at September 30, 2021 1,239.3 39.58 6.7 $ 20,593 Vested at September 30, 2021 759.7 39.06 5.3 $ 13,060 The aggregate intrinsic value of options exercised during the six months ended September 30, 2021 was $1.8 million.

Income Taxes

Income Taxes	6 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Income TaxesIncome taxes are recorded in our quarterly financial statements based on our estimated annual effective income tax rate, subject to adjustments for discrete events, should they occur. The effective tax rates used in the calculation of income taxes were 24.0% and 14.1% for the three months ended September 30, 2021 and 2020, respectively. The effective tax rates used in the calculation of income taxes were 24.2% and 19.8% for the six months ended September 30, 2021 and 2020, respectively. The lower effective tax rates in the three and six months ended September 30, 2020 were primarily due to final Global Intangible Low-Taxed Income regulations issued in July 2020, which resulted in the release of the valuation allowance on foreign tax credit carryforwards of $5.1 million.

Employee Retirement Plans

Employee Retirement Plans	6 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Employee Retirement Plans	Employee Retirement Plans The primary components of Net Periodic Benefits consist of the following: Three Months Ended September 30, Six Months Ended September 30, (In thousands) 2021 2020 2021 2020 Interest cost $ 278 $ 525 $ 556 $ 1,050 Expected return on assets (290) (647) (580) (1,294) Net periodic benefit income $ (12) $ (122) $ (24) $ (244) During the six months ended September 30, 2021, we contributed $0.2 million to our non-qualified defined benefit plan and no contributions to the qualified defined benefit plan. During the remainder of fiscal 2022, we expect to contribute an additional $0.2 million to our non-qualified plan and to make no contributions to the qualified plan.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and ContingenciesWe are involved from time to time in legal matters and other claims incidental to our business.  We review outstanding claims and proceedings internally and with external counsel as necessary to assess the probability and amount of a potential loss.  These assessments are re-evaluated at each reporting period and as new information becomes available to determine whether a reserve should be established or if any existing reserve should be adjusted.  The actual cost of resolving a claim or proceeding ultimately may be substantially different than the amount of the recorded reserve.  In addition, because it is not permissible under GAAP to establish a litigation reserve until the loss is both probable and estimable, in some cases there may be insufficient time to establish a reserve prior to the actual incurrence of the loss (upon verdict and judgment at trial, for example, or in the case of a quickly negotiated settlement).  We believe the reasonably possible losses from resolution of routine legal matters and other claims incidental to our business, taking our reserves into account, will not have a material adverse effect on our business, financial condition, or results of operations.

Concentrations of Risk

Concentrations of Risk	6 Months Ended
	Sep. 30, 2021
Risks and Uncertainties [Abstract]
Concentrations of Risk	Concentrations of Risk Our revenues are concentrated in the area of OTC Healthcare. We sell our products to mass merchandisers, drug, food, dollar, convenience and club stores and e-commerce channels. During the three and six months ended September 30, 2021, approximately 41.3% and 43.3%, respectively, of our gross revenues were derived from our five top selling brands. During the three and six months ended September 30, 2020, approximately 45.8% and 46.2%, respectively, of our gross revenues were derived from our five top selling brands. One customer, Walmart, accounted for more than 10% of our gross revenues for each of the periods presented. Walmart accounted for approximately 22.7% and 21.2%, respectively, of our gross revenues for the three and six months ended September 30, 2021. Walmart accounted for approximately 22.5% and 22.3%, respectively, of our gross revenues for the three and six months ended September 30, 2020. Our product distribution in the United States is managed by a third party through one primary distribution center in Clayton, Indiana. In addition, we operate one manufacturing facility for certain of our products located in Lynchburg, Virginia. A natural disaster, such as tornado, earthquake, flood, or fire, could damage our inventory and/or materially impair our ability to distribute our products to customers in a timely manner or at a reasonable cost. In addition, a serious disruption caused by performance or contractual issues with our third-party distribution manager or COVID-19 or other public health emergencies could also materially impact our product distribution. Any disruption as a result of third-party performance at our distribution center could result in increased costs, expense and/or shipping times, and could cause us to incur customer fees and penalties. In addition, any serious disruption to our Lynchburg manufacturing facility could materially impair our ability to manufacture many of the products associated with our acquisition of C.B. Fleet Company, Inc. ("Fleet"), which would also limit our ability to provide those products to customers in a timely manner or at a reasonable cost. We could also incur significantly higher costs and experience longer lead times if we need to replace our distribution center, the third-party distribution manager or the manufacturing facility. As a result, any serious disruption could have a material adverse effect on our business, financial condition and results of operations. At September 30, 2021, we had relationships with 121 third-party manufacturers. Of those, we had long-term contracts with 19 manufacturers that produced items that accounted for approximately 68.1% of gross sales for the six months ended September 30, 2021. At September 30, 2020, we had relationships with 113 third-party manufacturers. Of those, we had long-term contracts with 19 manufacturers that produced items that accounted for approximately 65.4% of gross sales for the six months ended September 30, 2020. The fact that we do not have long-term contracts with certain manufacturers means that they could cease manufacturing our products at any time and for any reason or initiate arbitrary and costly price increases, which could have a material adverse effect on our business and results of operations. Although we are continually in the process of negotiating long-term contracts with certain key manufacturers, we may not be able to reach a timely agreement, which could have a material adverse effect on our business and results of operations.

Business Segments

Business Segments	6 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Business Segments	Business Segments Segment information has been prepared in accordance with the Segment Reporting topic of the FASB ASC 280. Our current reportable segments consist of (i) North American OTC Healthcare and (ii) International OTC Healthcare. We evaluate the performance of our operating segments and allocate resources to these segments based primarily on contribution margin, which we define as gross profit less advertising and marketing expenses. The tables below summarize information about our reportable segments. Three Months Ended September 30, 2021 (In thousands) North American OTC International OTC Consolidated Total segment revenues* $ 251,728 $ 24,497 $ 276,225 Cost of sales 108,623 9,890 118,513 Gross profit 143,105 14,607 157,712 Advertising and marketing 36,493 4,237 40,730 Contribution margin $ 106,612 $ 10,370 116,982 Other operating expenses 38,424 Operating income $ 78,558 * Intersegment revenues of $0.7 million were eliminated from the North American OTC Healthcare segment. Six Months Ended September 30, 2021 (In thousands) North American OTC International OTC Consolidated Total segment revenues* $ 494,121 $ 51,285 $ 545,406 Cost of sales 208,027 20,655 228,682 Gross profit 286,094 30,630 316,724 Advertising and marketing 71,723 8,446 80,169 Contribution margin $ 214,371 $ 22,184 236,555 Other operating expenses 66,655 Operating income $ 169,900 * Intersegment revenues of $1.7 million were eliminated from the North American OTC Healthcare segment. Three Months Ended September 30, 2020 (In thousands) North American OTC International OTC Consolidated Total segment revenues* $ 216,575 $ 20,847 $ 237,422 Cost of sales 91,069 8,692 99,761 Gross profit 125,506 12,155 137,661 Advertising and marketing 34,014 4,327 38,341 Contribution margin $ 91,492 $ 7,828 99,320 Other operating expenses 26,417 Operating income $ 72,903 * Intersegment revenues of $0.6 million were eliminated from the North American OTC Healthcare segment. Six Months Ended September 30, 2020 (In thousands) North American OTC International OTC Consolidated Total segment revenues* $ 427,233 $ 39,583 $ 466,816 Cost of sales 178,896 16,391 195,287 Gross profit 248,337 23,192 271,529 Advertising and marketing 58,694 7,397 66,091 Contribution margin $ 189,643 $ 15,795 205,438 Other operating expenses 52,416 Operating income $ 153,022 * Intersegment revenues of $1.6 million were eliminated from the North American OTC Healthcare segment. The tables below summarize information about our segment revenues from similar product groups. Three Months Ended September 30, 2021 (In thousands) North American OTC International OTC Consolidated Analgesics $ 29,943 $ 396 $ 30,339 Cough & Cold 23,022 5,006 28,028 Women's Health 65,020 3,345 68,365 Gastrointestinal 37,964 8,641 46,605 Eye & Ear Care 37,818 2,988 40,806 Dermatologicals 32,365 839 33,204 Oral Care 22,893 3,278 26,171 Other OTC 2,703 4 2,707 Total segment revenues $ 251,728 $ 24,497 $ 276,225 Six Months Ended September 30, 2021 (In thousands) North American OTC International OTC Consolidated Analgesics $ 62,764 $ 802 $ 63,566 Cough & Cold 37,067 9,853 46,920 Women's Health 128,268 7,289 135,557 Gastrointestinal 80,330 18,845 99,175 Eye & Ear Care 73,805 6,446 80,251 Dermatologicals 63,515 1,778 65,293 Oral Care 43,860 6,267 50,127 Other OTC 4,512 5 4,517 Total segment revenues $ 494,121 $ 51,285 $ 545,406 Three Months Ended September 30, 2020 (In thousands) North American OTC International OTC Consolidated Analgesics $ 30,623 $ 267 $ 30,890 Cough & Cold 14,796 3,086 17,882 Women's Health 61,492 4,106 65,598 Gastrointestinal 31,718 6,379 38,097 Eye & Ear Care 26,767 3,037 29,804 Dermatologicals 27,875 836 28,711 Oral Care 21,944 3,134 25,078 Other OTC 1,360 2 1,362 Total segment revenues $ 216,575 $ 20,847 $ 237,422 Six Months Ended September 30, 2020 (In thousands) North American OTC International OTC Consolidated Analgesics $ 58,490 $ 541 $ 59,031 Cough & Cold 28,234 6,988 35,222 Women's Health 126,902 6,537 133,439 Gastrointestinal 61,768 12,084 73,852 Eye & Ear Care 49,619 5,582 55,201 Dermatologicals 55,495 1,535 57,030 Oral Care 44,110 6,313 50,423 Other OTC 2,615 3 2,618 Total segment revenues $ 427,233 $ 39,583 $ 466,816 Our total segment revenues by geographic area are as follows: Three Months Ended September 30, Six Months Ended September 30, 2021 2020 2021 2020 United States $ 236,151 $ 203,289 $ 462,818 $ 402,635 Rest of world 40,074 34,133 82,588 64,181 Total $ 276,225 $ 237,422 $ 545,406 $ 466,816 Our consolidated goodwill and intangible assets have been allocated to the reportable segments as follows: September 30, 2021 North American OTC International OTC Consolidated (In thousands) Goodwill $ 548,401 $ 30,396 $ 578,797 Intangible assets Indefinite-lived 2,399,717 81,873 2,481,590 Finite-lived, net 205,267 3,063 208,330 Intangible assets, net 2,604,984 84,936 2,689,920 Total $ 3,153,385 $ 115,332 $ 3,268,717 March 31, 2021 North American OTC International OTC Consolidated (In thousands) Goodwill $ 546,643 $ 31,436 $ 578,079 Intangible assets Indefinite-lived 2,195,617 86,371 2,281,988 Finite-lived, net 190,462 3,279 193,741 Intangible assets, net 2,386,079 89,650 2,475,729 Total $ 2,932,722 $ 121,086 $ 3,053,808

Business and Basis of Present_2

Business and Basis of Presentation (Policies)	6 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The unaudited Condensed Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. All significant intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, these Condensed Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented. Our fiscal year ends on March 31 st of each year. References in these Condensed Consolidated Financial Statements or related notes to a year (e.g., 2022) mean our fiscal year ending or ended on March 31 st of that year. Operating results for the six months ended September 30, 2021 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2022. These unaudited Condensed Consolidated Financial Statements and related notes should be read in conjunction with our audited
Use of Estimates	Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period.  Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ from those estimates. Our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances, inventory obsolescence, and accounting for income taxes and related uncertain tax positions.
Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements	Recently Adopted Accounting Pronouncements In December 2019, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes . The amendments in this update eliminate the need for an organization to analyze whether certain exceptions apply for tax purposes. It also simplifies GAAP for certain taxes. The amendments in these updates are effective for us for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. We adopted this standard effective April 1, 2021, and the adoption of this standard did not have a material impact on our Consolidated Financial Statements. Recently Issued Accounting Pronouncements In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting . This ASU provides optional expedient and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. In response to the concerns about structural risks of interbank offered rates (“IBORs”) and, particularly, the risk of cessation of the London Interbank Offered Rate (“LIBOR”), regulators in several jurisdictions around the world have undertaken reference rate reform initiatives to identify alternative reference rates that are more observable or transaction based and less susceptible to manipulation. The ASU provides companies with optional guidance to ease the potential accounting burden associated with transitioning away from reference rates that are expected to be discontinued. In January 2021, the FASB issued ASU 2021-01, which adds implementation guidance to clarify certain optional expedients in Topic 848. The ASUs can be adopted no later than December 31, 2022 with early adoption permitted. We are currently evaluating the effect of adopting this new accounting guidance.

Acquisition (Tables)

Acquisition (Tables)	6 Months Ended
	Sep. 30, 2021
Business Combinations [Abstract]
Schedule of Business Acquisitions, by Acquisition	The following table summarizes our preliminary allocation of the assets acquired and liabilities assumed as of the July 1, 2021 acquisition date. (In thousands) July 1, 2021 Inventories $ 6,432 Goodwill 1,758 Intangible assets 228,970 Total assets acquired 237,160 Accounts payable 591 Reserves for sales allowances and cash discounts 2,227 Other accrued liabilities 5,428 Total liabilities assumed 8,246 Total purchase price $ 228,914

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Sep. 30, 2021
Inventory Disclosure [Abstract]
Inventories	Inventories consist of the following: (In thousands) September 30, 2021 March 31, 2021 Components of Inventories Packaging and raw materials $ 11,333 $ 8,463 Work in process 344 326 Finished goods 96,241 106,170 Inventories $ 107,918 $ 114,959

Goodwill (Tables)

Goodwill (Tables)	6 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Reconciliation of the Activity Affecting Goodwill	A reconciliation of the activity affecting goodwill by operating segment is as follows: (In thousands) North American OTC International OTC Consolidated Balance - March 31, 2021 Goodwill $ 710,354 $ 32,683 $ 743,037 Accumulated impairment loss (163,711) (1,247) (164,958) Balance - March 31, 2021 546,643 31,436 578,079 2022 Additions 1,758 — 1,758 Effects of foreign currency exchange rates — (1,040) (1,040) Balance - September 30, 2021 Goodwill 712,112 31,643 743,755 Accumulated impairment loss (163,711) (1,247) (164,958) Balance - September 30, 2021 $ 548,401 $ 30,396 $ 578,797

Intangible Assets, net (Tables)

Intangible Assets, net (Tables)	6 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Reconciliation of the Activity Affecting Finite Lived Intangible Assets	A reconciliation of the activity affecting intangible assets, net is as follows: (In thousands) Indefinite- Finite-Lived Totals Gross Carrying Amounts Balance — March 31, 2021 $ 2,281,988 $ 389,347 $ 2,671,335 Additions 204,100 24,870 228,970 Effects of foreign currency exchange rates (4,498) (139) (4,637) Balance — September 30, 2021 2,481,590 414,078 2,895,668 Accumulated Amortization Balance — March 31, 2021 — 195,606 195,606 Additions — 10,228 10,228 Effects of foreign currency exchange rates — (86) (86) Balance — September 30, 2021 — 205,748 205,748 Intangible assets, net - September 30, 2021 $ 2,481,590 $ 208,330 $ 2,689,920
Reconciliation of the Activity Affecting Indefinite Lived Intangible Assets	A reconciliation of the activity affecting intangible assets, net is as follows: (In thousands) Indefinite- Finite-Lived Totals Gross Carrying Amounts Balance — March 31, 2021 $ 2,281,988 $ 389,347 $ 2,671,335 Additions 204,100 24,870 228,970 Effects of foreign currency exchange rates (4,498) (139) (4,637) Balance — September 30, 2021 2,481,590 414,078 2,895,668 Accumulated Amortization Balance — March 31, 2021 — 195,606 195,606 Additions — 10,228 10,228 Effects of foreign currency exchange rates — (86) (86) Balance — September 30, 2021 — 205,748 205,748 Intangible assets, net - September 30, 2021 $ 2,481,590 $ 208,330 $ 2,689,920
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Finite-lived intangible assets are expected to be amortized over their estimated useful life, which ranges from a period of 10 to 30 years, and the estimated amortization expense for each of the five succeeding years and the periods thereafter is as follows (in thousands): (In thousands) Year Ending March 31, Amount 2022 (remaining six months ended March 31, 2022) $ 10,721 2023 21,413 2024 21,379 2025 19,287 2026 16,904 Thereafter 118,626 $ 208,330

Leases (Tables)

Leases (Tables)	6 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Components of Lease Expense	The components of lease expense for the three and six months ended September 30, 2021 and 2020 were as follows: Three Months Ended September 30, Six Months Ended September 30, (In thousands) 2021 2020 2021 2020 Finance lease cost: Amortization of right-of-use assets $ 642 $ 443 $ 1,284 $ 768 Interest on lease liabilities 63 59 129 109 Operating lease cost 1,683 1,692 3,370 3,389 Short term lease cost 24 22 46 45 Variable lease cost 11,998 12,303 23,649 24,010 Sublease income — (55) — (109) Total net lease cost $ 14,410 $ 14,464 $ 28,478 $ 28,212 The weighted average remaining lease term and weighted average discount rate were as follows: September 30, 2021 Weighted average remaining lease term (years) Operating leases 4.41 Finance leases 3.00 Weighted average discount rate Operating leases 3.00 % Finance leases 2.98 %
Maturities of Operating Leases	As of September 30, 2021, the maturities of lease liabilities were as follows: (In thousands) Year Ending March 31, Operating Leases Finance Total 2022 (Remaining six months ending March 31, 2022) $ 3,673 $ 1,413 $ 5,086 2023 6,211 2,826 9,037 2024 6,416 2,826 9,242 2025 4,220 1,412 5,632 2026 1,898 — 1,898 Thereafter 3,608 — 3,608 Total undiscounted lease payments 26,026 8,477 34,503 Less amount of lease payments representing interest (1,948) (357) (2,305) Total present value of lease payments $ 24,078 $ 8,120 $ 32,198
Maturities of Finance Leases	As of September 30, 2021, the maturities of lease liabilities were as follows: (In thousands) Year Ending March 31, Operating Leases Finance Total 2022 (Remaining six months ending March 31, 2022) $ 3,673 $ 1,413 $ 5,086 2023 6,211 2,826 9,037 2024 6,416 2,826 9,242 2025 4,220 1,412 5,632 2026 1,898 — 1,898 Thereafter 3,608 — 3,608 Total undiscounted lease payments 26,026 8,477 34,503 Less amount of lease payments representing interest (1,948) (357) (2,305) Total present value of lease payments $ 24,078 $ 8,120 $ 32,198

Other Accrued Liabilities (Tabl

Other Accrued Liabilities (Tables)	6 Months Ended
	Sep. 30, 2021
Payables and Accruals [Abstract]
Other Accrued Liabilities	Other accrued liabilities consist of the following: (In thousands) September 30, 2021 March 31, 2021 Accrued marketing costs $ 44,603 $ 29,955 Accrued compensation costs 11,638 14,074 Accrued broker commissions 943 1,023 Income taxes payable 1,551 1,652 Accrued professional fees 4,743 4,472 Accrued production costs 3,790 2,882 Accrued sales tax 977 2,368 Other accrued liabilities 10,405 4,976 $ 78,650 $ 61,402

Long-Term Debt (Tables)

Long-Term Debt (Tables)	6 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Schedule of Long-term Debt	Long-term debt consists of the following, as of the dates indicated: (In thousands, except percentages) September 30, 2021 March 31, 2021 2021 Senior Notes bearing interest at 3.750%, with interest payable on April 1 and October 1 of each year. The 2021 Senior Notes mature on April 1, 2031. $ 600,000 $ 600,000 2019 Senior Notes bearing interest at 5.125%, with interest payable on January 15 and July 15 of each year. The 2019 Senior Notes mature on January 15, 2028. 400,000 400,000 2012 Term B-5 Loans bearing interest at the Borrower's option at either LIBOR plus a margin of 2.00%, with a LIBOR floor of 0.00%, or an alternate base rate plus a margin of 1.00% per annum, with a base rate floor of 1.00%, due on January 24, 2024. — 495,000 2012 Term B-5 Loans bearing interest at the Borrower's option at either LIBOR plus a margin of 2.00%, with a LIBOR floor of 0.50%, or an alternate base rate plus a margin of 1.00% per annum, due on July 1, 2028. 600,000 — 2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on December 11, 2024. 20,000 — Total long-term debt (including current portion) 1,620,000 1,495,000 Current portion of long-term debt 6,000 — Long-term debt 1,614,000 1,495,000 Less: unamortized debt costs (21,019) (15,347) Long-term debt, net $ 1,592,981 $ 1,479,653
Aggregate Future Principal Payments	As of September 30, 2021, aggregate future principal payments required in accordance with the terms of the 2012 Term B-5 Loans, 2012 ABL Revolver and the indentures governing the senior unsecured notes due 2031 (the "2021 Senior Notes") and the senior unsecured notes due 2028 (the "2019 Senior Notes") are as follows: (In thousands) Year Ending March 31, Amount 2022 (remaining six months ending March 31, 2022) $ 3,000 2023 6,000 2024 6,000 2025 26,000 2026 6,000 Thereafter 1,573,000 $ 1,620,000

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Summary of Carry Amounts and Fair Value Measurements	The summary below details the carrying amounts and estimated fair values of these instruments at September 30, 2021 and March 31, 2021. September 30, 2021 March 31, 2021 (In thousands) Carrying Value Fair Value Carrying Value Fair Value 2021 Senior Notes $ 600,000 $ 577,500 $ 600,000 $ 570,000 2019 Senior Notes 400,000 416,000 400,000 417,000 2012 Term B-5 Loans, Amendment No. 5 — — 495,000 493,763 2012 Term B-5 Loans, Amendment No. 6 600,000 599,250 — — 2012 ABL Revolver 20,000 20,000 — — Interest rate swaps 973 973 2,363 2,363

Derivative Instruments (Tables)

Derivative Instruments (Tables)	6 Months Ended
	Sep. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	The following tables summarize the fair values of our derivative instrument as of the end of the periods shown: September 30, 2021 (In thousands) Hedge Type Final Settlement Date Notional Amount Other Accrued Liabilities Other Long-Term Liabilities Interest rate swap Cash flow 1/31/2022 $ 200,000 $ (973) $ — Total fair value $ (973) $ — March 31, 2021 (In thousands) Hedge Type Final Settlement Date Notional Amount Other Accrued Liabilities Other Long-Term Liabilities Interest rate swap Cash flow 1/31/2022 $ 200,000 $ (2,363) $ — Total fair value $ (2,363) $ —
Derivative Instruments, Gain (Loss)	The following table summarizes our interest rate swaps, net of tax, for the periods shown: Three Months Ended September 30, Six Months Ended September 30, (In thousands) Location 2021 2020 2021 2020 Gain Recognized in Other Comprehensive Loss (effective portion) Other comprehensive income (loss) $ 550 $ 985 $ 1,070 $ 1,294 Loss Reclassified from Accumulated Other Comprehensive Loss into Income Interest expense $ (732) $ (1,396) $ (1,450) $ (2,422)

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Sep. 30, 2021
Stockholders' Equity Note [Abstract]
Class of Treasury Stock	Our share repurchases consisted of the following: Three Months Ended September 30, Six Months Ended September 30, 2021 2020 2021 2020 Shares repurchased pursuant to the provisions of the various employee restricted stock awards: Number of shares — — 63,314 31,117 Average price per share $ — $ — $46.04 $39.91 Total amount repurchased $ — $ — $2.9 million $1.2 million Shares repurchased in conjunction with our share repurchase program: Number of shares — 28,865 — 28,865 Average price per share $ — $34.55 $ — $34.55 Total amount repurchased $ — $1.0 million $ — $1.0 million

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	6 Months Ended
	Sep. 30, 2021
Stockholders' Equity Note [Abstract]
Schedule of Accumulated Other Comprehensive Loss	Accumulated other comprehensive loss consisted of the following at September 30, 2021 and March 31, 2021: (In thousands) September 30, 2021 March 31, 2021 Components of Accumulated Other Comprehensive Loss Cumulative translation adjustment $ (24,597) $ (18,908) Unrealized loss on interest rate swaps, net of tax of $224 and $543, respectively (749) (1,819) Unrecognized net gain (loss) on pension plans, net of tax of $(276) and $(276), respectively 926 926 Accumulated other comprehensive loss, net of tax $ (24,420) $ (19,801)

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Computation of Basic and Diluted Earnings Per Share	The following table sets forth the computation of basic and diluted earnings per share: Three Months Ended September 30, Six Months Ended September 30, (In thousands, except per share data) 2021 2020 2021 2020 Numerator Net income $ 45,325 $ 44,589 $ 103,080 $ 88,295 Denominator Denominator for basic earnings per share — weighted average shares outstanding 50,232 50,330 50,186 50,297 Dilutive effect of unvested restricted stock units and options issued to employees and directors 559 331 545 375 Denominator for diluted earnings per share 50,791 50,661 50,731 50,672 Earnings per Common Share: Basic earnings per share $ 0.90 $ 0.89 $ 2.05 $ 1.76 Diluted earnings per share $ 0.89 $ 0.88 $ 2.03 $ 1.74

Share-Based Compensation (Table

Share-Based Compensation (Tables)	6 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Compensation Expense Information	The following table provides information regarding our stock-based compensation: Three Months Ended September 30, Six Months Ended September 30, (In thousands) 2021 2020 2021 2020 Pre-tax share-based compensation costs charged against income $ 3,219 $ 2,892 $ 5,097 $ 4,356 Income tax benefit recognized on compensation costs $ 369 $ 451 $ 512 $ 563 Total fair value of options and RSUs vested during the period $ 937 $ 1,015 $ 7,943 $ 6,796 Cash received from the exercise of stock options $ 503 $ 69 $ 2,707 $ 1,285 Tax benefits realized from tax deductions resulting from RSU issuances and stock option exercises $ 350 $ 4 $ 2,071 $ 948
Summary of Restricted Shares	A summary of the RSUs granted under the 2005 Plan and the 2020 Plan is presented below: RSUs Shares (in thousands) Weighted Six Months Ended September 30, 2020 Unvested at March 31, 2020 387.9 $ 33.11 Granted 179.7 40.22 Vested (100.2) 42.94 Forfeited (4.7) 56.11 Unvested at September 30, 2020 462.7 33.51 Vested at September 30, 2020 150.4 31.98 Six Months Ended September 30, 2021 Unvested at March 31, 2021 457.0 $ 33.52 Granted 170.8 45.32 Vested (162.3) 32.99 Forfeited (24.6) 30.54 Unvested at September 30, 2021 440.9 38.45 Vested at September 30, 2021 152.3 33.92
Fair Value of Options Granted	The fair value of each award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions presented below: Six Months Ended September 30, 2021 2020 Expected volatility 31.1% - 31.9% 32.1% - 32.2% Expected dividends $ — $ — Expected term in years 6.0 to 7.0 6.0 to 7.0 Risk-free rate 1.0% to 1.3% 0.5% Weighted average grant date fair value of options granted $ 14.87 $ 12.91
Stock Option Activity	A summary of option activity under the 2005 Plan and the 2020 Plan is as follows: Options Shares (in thousands) Weighted Weighted Aggregate Six Months Ended September 30, 2020 Outstanding at March 31, 2020 1,020.2 $ 35.90 Granted 249.9 39.98 Exercised (62.8) 20.46 Forfeited — — Expired — — Outstanding at September 30, 2020 1,207.3 37.55 7.0 $ 5,032 Vested at September 30, 2020 699.1 39.39 5.6 $ 3,430 Six Months Ended September 30, 2021 Outstanding at March 31, 2021 1,114.9 $ 37.92 Granted 234.2 44.74 Exercised (87.6) 30.91 Forfeited (13.7) 37.83 Expired (8.5) 56.63 Outstanding at September 30, 2021 1,239.3 39.58 6.7 $ 20,593 Vested at September 30, 2021 759.7 39.06 5.3 $ 13,060

Employee Retirement Plans (Tabl

Employee Retirement Plans (Tables)	6 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Schedule of Primary Components of Net Periodic Benefits	The primary components of Net Periodic Benefits consist of the following: Three Months Ended September 30, Six Months Ended September 30, (In thousands) 2021 2020 2021 2020 Interest cost $ 278 $ 525 $ 556 $ 1,050 Expected return on assets (290) (647) (580) (1,294) Net periodic benefit income $ (12) $ (122) $ (24) $ (244)

Business Segments (Tables)

Business Segments (Tables)	6 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Information About Our Operating and Reportable Segments	The tables below summarize information about our reportable segments. Three Months Ended September 30, 2021 (In thousands) North American OTC International OTC Consolidated Total segment revenues* $ 251,728 $ 24,497 $ 276,225 Cost of sales 108,623 9,890 118,513 Gross profit 143,105 14,607 157,712 Advertising and marketing 36,493 4,237 40,730 Contribution margin $ 106,612 $ 10,370 116,982 Other operating expenses 38,424 Operating income $ 78,558 * Intersegment revenues of $0.7 million were eliminated from the North American OTC Healthcare segment. Six Months Ended September 30, 2021 (In thousands) North American OTC International OTC Consolidated Total segment revenues* $ 494,121 $ 51,285 $ 545,406 Cost of sales 208,027 20,655 228,682 Gross profit 286,094 30,630 316,724 Advertising and marketing 71,723 8,446 80,169 Contribution margin $ 214,371 $ 22,184 236,555 Other operating expenses 66,655 Operating income $ 169,900 * Intersegment revenues of $1.7 million were eliminated from the North American OTC Healthcare segment. Three Months Ended September 30, 2020 (In thousands) North American OTC International OTC Consolidated Total segment revenues* $ 216,575 $ 20,847 $ 237,422 Cost of sales 91,069 8,692 99,761 Gross profit 125,506 12,155 137,661 Advertising and marketing 34,014 4,327 38,341 Contribution margin $ 91,492 $ 7,828 99,320 Other operating expenses 26,417 Operating income $ 72,903 * Intersegment revenues of $0.6 million were eliminated from the North American OTC Healthcare segment. Six Months Ended September 30, 2020 (In thousands) North American OTC International OTC Consolidated Total segment revenues* $ 427,233 $ 39,583 $ 466,816 Cost of sales 178,896 16,391 195,287 Gross profit 248,337 23,192 271,529 Advertising and marketing 58,694 7,397 66,091 Contribution margin $ 189,643 $ 15,795 205,438 Other operating expenses 52,416 Operating income $ 153,022 * Intersegment revenues of $1.6 million were eliminated from the North American OTC Healthcare segment.
Information About Our Revenues from Similar Product Groups	The tables below summarize information about our segment revenues from similar product groups. Three Months Ended September 30, 2021 (In thousands) North American OTC International OTC Consolidated Analgesics $ 29,943 $ 396 $ 30,339 Cough & Cold 23,022 5,006 28,028 Women's Health 65,020 3,345 68,365 Gastrointestinal 37,964 8,641 46,605 Eye & Ear Care 37,818 2,988 40,806 Dermatologicals 32,365 839 33,204 Oral Care 22,893 3,278 26,171 Other OTC 2,703 4 2,707 Total segment revenues $ 251,728 $ 24,497 $ 276,225 Six Months Ended September 30, 2021 (In thousands) North American OTC International OTC Consolidated Analgesics $ 62,764 $ 802 $ 63,566 Cough & Cold 37,067 9,853 46,920 Women's Health 128,268 7,289 135,557 Gastrointestinal 80,330 18,845 99,175 Eye & Ear Care 73,805 6,446 80,251 Dermatologicals 63,515 1,778 65,293 Oral Care 43,860 6,267 50,127 Other OTC 4,512 5 4,517 Total segment revenues $ 494,121 $ 51,285 $ 545,406 Three Months Ended September 30, 2020 (In thousands) North American OTC International OTC Consolidated Analgesics $ 30,623 $ 267 $ 30,890 Cough & Cold 14,796 3,086 17,882 Women's Health 61,492 4,106 65,598 Gastrointestinal 31,718 6,379 38,097 Eye & Ear Care 26,767 3,037 29,804 Dermatologicals 27,875 836 28,711 Oral Care 21,944 3,134 25,078 Other OTC 1,360 2 1,362 Total segment revenues $ 216,575 $ 20,847 $ 237,422 Six Months Ended September 30, 2020 (In thousands) North American OTC International OTC Consolidated Analgesics $ 58,490 $ 541 $ 59,031 Cough & Cold 28,234 6,988 35,222 Women's Health 126,902 6,537 133,439 Gastrointestinal 61,768 12,084 73,852 Eye & Ear Care 49,619 5,582 55,201 Dermatologicals 55,495 1,535 57,030 Oral Care 44,110 6,313 50,423 Other OTC 2,615 3 2,618 Total segment revenues $ 427,233 $ 39,583 $ 466,816
Information About Our Segment Revenues by Geographic Area	Our total segment revenues by geographic area are as follows: Three Months Ended September 30, Six Months Ended September 30, 2021 2020 2021 2020 United States $ 236,151 $ 203,289 $ 462,818 $ 402,635 Rest of world 40,074 34,133 82,588 64,181 Total $ 276,225 $ 237,422 $ 545,406 $ 466,816
Information About Our Consolidated Goodwill and Intangible Assets Allocated to Reportable Segments	Our consolidated goodwill and intangible assets have been allocated to the reportable segments as follows: September 30, 2021 North American OTC International OTC Consolidated (In thousands) Goodwill $ 548,401 $ 30,396 $ 578,797 Intangible assets Indefinite-lived 2,399,717 81,873 2,481,590 Finite-lived, net 205,267 3,063 208,330 Intangible assets, net 2,604,984 84,936 2,689,920 Total $ 3,153,385 $ 115,332 $ 3,268,717 March 31, 2021 North American OTC International OTC Consolidated (In thousands) Goodwill $ 546,643 $ 31,436 $ 578,079 Intangible assets Indefinite-lived 2,195,617 86,371 2,281,988 Finite-lived, net 190,462 3,279 193,741 Intangible assets, net 2,386,079 89,650 2,475,729 Total $ 2,932,722 $ 121,086 $ 3,053,808

Acquisition (Narrative) (Detail

Acquisition (Narrative) (Details) - USD ($) $ in Thousands	Jul. 01, 2021	Sep. 30, 2021	Mar. 31, 2021
Business Acquisition [Line Items]
Goodwill		$ 578,797	$ 578,079
Akorn Operating Company LLC
Business Acquisition [Line Items]
Purchase price	$ 228,900
Supply commitment, term of agreement		3 years
Business combination, non-amortizable intangible assets, allocated amount	204,100
Business combination, amortizable intangible assets, allocated amount	24,900
Intangible asset, useful life		12 years 6 months
Goodwill	1,758
Customer Relationships | Akorn Operating Company LLC
Business Acquisition [Line Items]
Business combination, non-amortizable intangible assets, allocated amount	19,600
Trademarks | Akorn Operating Company LLC
Business Acquisition [Line Items]
Business combination, non-amortizable intangible assets, allocated amount	5,300
General and Administrative Expense | Akorn Operating Company LLC
Business Acquisition [Line Items]
Business acquisition, transaction costs	$ 5,100

Acquisition (Allocation of Asse

Acquisition (Allocation of Assets Acquired and Liabilities Assumed) (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Jul. 01, 2021	Mar. 31, 2021
Purchase Price
Goodwill	$ 578,797		$ 578,079
Akorn Operating Company LLC
Purchase Price
Inventories		$ 6,432
Goodwill		1,758
Intangible assets		228,970
Total assets acquired		237,160
Accounts payable		591
Reserves for sales allowances and cash discounts		2,227
Other accrued liabilities		5,428
Total liabilities assumed		8,246
Total purchase price		$ 228,914

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Mar. 31, 2021
Inventory Disclosure [Abstract]
Packaging and raw materials	$ 11,333	$ 8,463
Work in process	344	326
Finished goods	96,241	106,170
Inventories	$ 107,918	$ 114,959

Inventories - Narrative (Detail

Inventories - Narrative (Details) - USD ($) $ in Millions	Sep. 30, 2021	Mar. 31, 2021
Inventory Disclosure [Abstract]
Inventory valuation reserves related to obsolete and slow-moving inventory	$ 5.1	$ 4

Goodwill - Schedule of Changes

Goodwill - Schedule of Changes (Details) $ in Thousands	6 Months Ended
	Sep. 30, 2021USD ($)
Goodwill [Roll Forward]
Goodwill	$ 743,037
Accumulated impairment loss, beginning	(164,958)
Goodwill, net	578,079
Goodwill, Acquired During Period	1,758
Effects of foreign currency exchange rates	(1,040)
Goodwill, gross, ending	743,755
Accumulated impairment loss, ending	(164,958)
Goodwill, net, ending	578,797
North American OTC Healthcare
Goodwill [Roll Forward]
Goodwill	710,354
Accumulated impairment loss, beginning	(163,711)
Goodwill, net	546,643
Goodwill, Acquired During Period	1,758
Effects of foreign currency exchange rates	0
Goodwill, gross, ending	712,112
Accumulated impairment loss, ending	(163,711)
Goodwill, net, ending	548,401
International OTC Healthcare
Goodwill [Roll Forward]
Goodwill	32,683
Accumulated impairment loss, beginning	(1,247)
Goodwill, net	31,436
Goodwill, Acquired During Period	0
Effects of foreign currency exchange rates	(1,040)
Goodwill, gross, ending	31,643
Accumulated impairment loss, ending	(1,247)
Goodwill, net, ending	$ 30,396

Goodwill - Narrative (Details)

Goodwill - Narrative (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Jul. 01, 2021	Mar. 31, 2021
Goodwill [Line Items]
Goodwill	$ 578,797		$ 578,079
Akorn Operating Company LLC
Goodwill [Line Items]
Goodwill		$ 1,758

Intangible Assets, net - Activi

Intangible Assets, net - Activity Affecting Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Mar. 31, 2021
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived trademarks, beginning balance			$ 2,281,988
Indefinite-lived trademarks, ending balance	$ 2,481,590		2,481,590
Intangible Assets, Gross [Abstract]
Totals, gross, beginning balance			2,671,335
Intangible assets, additions			228,970
Intangible Assets, Translation Adjustments Gain (Loss)			(4,637)
Totals, gross, ending balance	2,895,668		2,895,668
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Accumulated amortization, beginning balance			195,606
Accumulated amortization, additions	5,300	$ 4,900	10,228	$ 9,800
Accumulated amortization, effects of foreign exchange rates			(86)
Accumulated amortization, ending balance	205,748		205,748
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived, net	208,330		208,330		$ 193,741
Intangible Assets, Net [Abstract]
Intangible assets, net	2,689,920		2,689,920		$ 2,475,729
Finite-Lived Trademarks and Customer Relationships
Finite-Lived Intangible Assets, Gross [Abstract]
Finite-lived trademarks and customer relationships, beginning balance			389,347
Finite-Lived trademarks and customer relationships, additions			24,870
Finite-lived trademarks and customer relationships, effects of foreign currency exchange rate			(139)
Finite-lived trademarks and customer relationships, ending balance	414,078		414,078
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Accumulated amortization, beginning balance			195,606
Accumulated amortization, additions			10,228
Accumulated amortization, effects of foreign exchange rates			(86)
Accumulated amortization, ending balance	205,748		205,748
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived, net	208,330		208,330
Indefinite- Lived Trademarks
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived trademarks, beginning balance			2,281,988
Indefinite-lived trade marks, additions			204,100
Indefinite lived trademarks, effects of foreign currency exchange rate			(4,498)
Indefinite-lived trademarks, ending balance	$ 2,481,590		$ 2,481,590

Intangible Assets, net - Narrat

Intangible Assets, net - Narrative (Details) - USD ($)	Jul. 01, 2021	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Finite-Lived Intangible Assets [Line Items]
Amortization expense		$ 5,300,000		$ 4,900,000	$ 10,228,000	$ 9,800,000
Intangible assets, additions					$ 228,970,000
Impairment of intangible assets			$ 0
Akorn Operating Company LLC
Finite-Lived Intangible Assets [Line Items]
Intangible assets, additions	$ 229,000,000
Minimum
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life					10 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life					30 years

Intangible Assets, net - Future

Intangible Assets, net - Future Amortization of Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
2022 (remaining six months ended March 31, 2022)	$ 10,721
2023	21,413
2024	21,379
2025	19,287
2026	16,904
Thereafter	118,626
Finite-lived intangible assets, net	$ 208,330	$ 193,741

Leases - Lease Cost (Details)

Leases - Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Leases [Abstract]
Amortization of right-of-use assets	$ 642	$ 443	$ 1,284	$ 768
Interest on lease liabilities	63	59	129	109
Operating lease cost	1,683	1,692	3,370	3,389
Short term lease cost	24	22	46	45
Variable lease cost	11,998	12,303	23,649	24,010
Sublease income	0	(55)	0	(109)
Total net lease cost	$ 14,410	$ 14,464	$ 28,478	$ 28,212

Leases - Lease Maturities (Deta

Leases - Lease Maturities (Details) $ in Thousands	Sep. 30, 2021USD ($)
Operating Leases
2022 (Remaining six months ending March 31, 2022)	$ 3,673
2023	6,211
2024	6,416
2025	4,220
2026	1,898
Thereafter	3,608
Total undiscounted lease payments	26,026
Less amount of lease payments representing interest	(1,948)
Total present value of lease payments	24,078
Finance Lease
2022 (Remaining six months ending March 31, 2022)	1,413
2023	2,826
2024	2,826
2025	1,412
2026	0
Thereafter	0
Total undiscounted lease payments	8,477
Total present value of lease payments	(357)
Total present value of lease payments	8,120
Total
2022 (Remaining six months ending March 31, 2022)	5,086
2023	9,037
2024	9,242
2025	5,632
2026	1,898
Thereafter	3,608
Total undiscounted lease payments	34,503
Less amount of lease payments representing interest	(2,305)
Total present value of lease payments	$ 32,198

Leases - Additional Information

Leases - Additional Information (Details)	Sep. 30, 2021
Weighted average remaining lease term (years)
Operating leases	4 years 4 months 28 days
Finance leases	3 years
Weighted average discount rate
Operating leases	3.00%
Finance leases	2.98%

Other Accrued Liabilities (Deta

Other Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Mar. 31, 2021
Payables and Accruals [Abstract]
Accrued marketing costs	$ 44,603	$ 29,955
Accrued compensation costs	11,638	14,074
Accrued broker commissions	943	1,023
Income taxes payable	1,551	1,652
Accrued professional fees	4,743	4,472
Accrued production costs	3,790	2,882
Accrued sales tax	977	2,368
Other accrued liabilities	10,405	4,976
Other accrued liabilities	$ 78,650	$ 61,402

Long-Term Debt - Schedule of Lo

Long-Term Debt - Schedule of Long-term Debt (Details) - USD ($) $ in Thousands	6 Months Ended
	Sep. 30, 2021	Mar. 31, 2021
Debt Instrument [Line Items]
Total long-term debt (including current portion)	$ 1,620,000	$ 1,495,000
Current portion of long-term debt	6,000	0
Long-term debt, net	1,614,000	1,495,000
Less: unamortized debt costs	(21,019)	(15,347)
Long-term debt, net	1,592,981	1,479,653
2012 ABL Revolver | Revolving Credit Facility
Debt Instrument [Line Items]
Total long-term debt (including current portion)	$ 20,000	0
Senior Notes | 2021 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate	3.75%
Total long-term debt (including current portion)	$ 600,000	600,000
Senior Notes | 2019 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate	5.125%
Total long-term debt (including current portion)	$ 400,000	400,000
Term B-5 Loans | 2012 Senior Notes
Debt Instrument [Line Items]
Total long-term debt (including current portion)	$ 0	495,000
Term B-5 Loans | 2012 Senior Notes | LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	2.00%
Debt instrument, variable rate, minimum	0.00%
Term B-5 Loans | 2012 Senior Notes | Base Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	1.00%
Debt instrument, variable rate, minimum	1.00%
Term B-5 Loans | 2012 ABL Revolver | Revolving Credit Facility
Debt Instrument [Line Items]
Total long-term debt (including current portion)	$ 600,000	$ 0
Term B-5 Loans | 2012 ABL Revolver | LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	2.00%
Debt instrument, variable rate, minimum	0.50%
Term B-5 Loans | 2012 ABL Revolver | Base Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	1.00%

Long-Term Debt - Narrative (Det

Long-Term Debt - Narrative (Details)	Jul. 01, 2021USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Mar. 31, 2021USD ($)	Jan. 31, 2020USD ($)
Debt Instrument [Line Items]
Total long-term debt (including current portion)		$ 1,620,000,000		$ 1,620,000,000		$ 1,495,000,000
Debt instrument, period payment, percentage of principal amount	0.0025
Loss on extinguishment of debt		2,122,000	$ 0	2,122,000	$ 0
Secured Debt
Debt Instrument [Line Items]
Debt instrument, face amount	$ 600,000,000
Secured Debt | LIBOR
Debt Instrument [Line Items]
Debt instrument, alternative basis spread on variable rate	0.0100
Secured Debt | Minimum | LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	2.00%
Secured Debt | Maximum | LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	0.50%
Interest rate swaps | Designated as Hedging Instrument
Debt Instrument [Line Items]
Derivative, notional amount		200,000,000		200,000,000			$ 400,000,000
2013 Senior Notes
Debt Instrument [Line Items]
Loss on extinguishment of debt				2,100,000
Revolving Credit Facility | 2012 ABL Revolver
Debt Instrument [Line Items]
Total long-term debt (including current portion)		20,000,000		20,000,000		$ 0
Borrowing capacity		$ 104,600,000		$ 104,600,000

Long-Term Debt - Maturities of

Long-Term Debt - Maturities of Long-term Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Mar. 31, 2021
Aggregate Future Principal Payments
2022 (remaining six months ending March 31, 2022)	$ 3,000
2023	6,000
2024	6,000
2025	26,000
2026	6,000
Thereafter	1,573,000
Total long-term debt (including current portion)	$ 1,620,000	$ 1,495,000

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Mar. 31, 2021
Carrying Value | Interest rate swaps
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Interest rate swaps	$ 973	$ 2,363
Senior Notes | 2021 Senior Notes | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	600,000	600,000
Senior Notes | 2019 Senior Notes | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	400,000	400,000
Term Loans | Term B-5 Loans | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	0	495,000
Term Loans | Loans Payable, Term B-5 Amendment No. 6 | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	600,000	0
Revolving Credit Facility | 2012 ABL Revolver | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
2012 ABL Revolver	20,000	0
Fair Value, Measurements, Recurring | Fair Value | Fair Value, Inputs, Level 2 | Interest rate swaps
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Interest rate swaps	973	2,363
Fair Value, Measurements, Recurring | Senior Notes | 2021 Senior Notes | Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	577,500	570,000
Fair Value, Measurements, Recurring | Senior Notes | 2019 Senior Notes | Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	416,000	417,000
Fair Value, Measurements, Recurring | Term Loans | Term B-5 Loans | Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	0	493,763
Fair Value, Measurements, Recurring | Term Loans | Loans Payable, Term B-5 Amendment No. 6 | Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	599,250	0
Fair Value, Measurements, Recurring | Revolving Credit Facility | 2012 ABL Revolver | Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
2012 ABL Revolver	$ 20,000	$ 0

Derivative Instruments (Details

Derivative Instruments (Details)	Sep. 30, 2021USD ($)	Jan. 31, 2021agreement	Jan. 31, 2020USD ($)agreement
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, number of instruments held | agreement			2
Derivative, number of instruments settled | agreement		1
Interest rate swaps
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate cash flow hedge loss to be reclassified during next 12 months, net | $	$ 1,000,000
Interest rate swaps | Designated as Hedging Instrument
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount | $	$ 200,000,000		$ 400,000,000

Derivative Instruments - Summar

Derivative Instruments - Summary of Fair Values of Derivatives (Details) - Interest rate swaps - Designated as Hedging Instrument - USD ($)	Sep. 30, 2021	Mar. 31, 2021	Jan. 31, 2020
Derivatives, Fair Value [Line Items]
Derivative, notional amount	$ 200,000,000		$ 400,000,000
Cash Flow Hedging
Derivatives, Fair Value [Line Items]
Derivative, notional amount	200,000,000	$ 200,000,000
Other Accrued Liabilities
Derivatives, Fair Value [Line Items]
Derivative liability, fair value	(973,000)	(2,363,000)
Other Accrued Liabilities | Cash Flow Hedging
Derivatives, Fair Value [Line Items]
Derivative liability, fair value	(973,000)	(2,363,000)
Other Long-Term Liabilities
Derivatives, Fair Value [Line Items]
Derivative liability, fair value	0	0
Other Long-Term Liabilities | Cash Flow Hedging
Derivatives, Fair Value [Line Items]
Derivative liability, fair value	$ 0	$ 0

Derivative Instruments - Summ_2

Derivative Instruments - Summary of Interest Rate Swaps (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gain Recognized in Other Comprehensive Loss (effective portion)	$ 550	$ 985	$ 1,070	$ 1,294
Designated as Hedging Instrument | Interest rate swaps
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gain Recognized in Other Comprehensive Loss (effective portion)	550	985	1,070	1,294
Designated as Hedging Instrument | Interest expense | Interest rate swaps
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Loss Reclassified from Accumulated Other Comprehensive Loss into Income	$ (732)	$ (1,396)	$ (1,450)	$ (2,422)

Stockholders' Equity (Details)

Stockholders' Equity (Details)	6 Months Ended
	Sep. 30, 2021USD ($)vote$ / sharesshares	Mar. 31, 2021$ / sharesshares
Stockholders' Equity Note [Abstract]
Common stock, shares authorized | shares	250,000,000	250,000,000
Common stock, par value (in USD per share) | $ / shares	$ 0.01	$ 0.01
Preferred stock, shares authorized | shares	5,000,000	5,000,000
Preferred stock, par value (in USD per share) | $ / shares	$ 0.01	$ 0.01
Voting rights, number of votes per common share owned | vote	1
Dividends declared on common stock | $	$ 0

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Repurchased Shares (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Class of Stock [Line Items]
Total amount repurchased		$ 997	$ 2,916	$ 2,239
Share Repurchase Program
Class of Stock [Line Items]
Number of shares	0	28,865	0	28,865
Average price per share (in USD per share)	$ 0	$ 34.55	$ 0	$ 34.55
Total amount repurchased	$ 0	$ 1,000	$ 0	$ 1,000
Restricted Shares
Class of Stock [Line Items]
Number of shares	0	0	63,314	31,117
Average price per share (in USD per share)	$ 0	$ 0	$ 46.04	$ 39.91
Total amount repurchased	$ 0	$ 0	$ 2,900	$ 1,200

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Sep. 30, 2021	Mar. 31, 2021	Jun. 30, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shareholders' equity	$ 1,461,647	$ 1,358,298	$ 1,416,247	$ 1,278,217	$ 1,227,014	$ 1,170,971
Accumulated other comprehensive loss, net of tax
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shareholders' equity	(24,420)	(19,801)	$ (20,773)	$ (28,612)	$ (33,262)	$ (44,161)
Cumulative translation adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shareholders' equity	(24,597)	(18,908)
Unrealized loss on interest rate swaps, net of tax of $224 and $543, respectively
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shareholders' equity	(749)	(1,819)
Other comprehensive loss, cash flow hedge, reclassification tax	224	543
Unrecognized net gain (loss) on pension plans, net of tax of $(276) and $(276), respectively
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shareholders' equity	926	926
Other comprehensive loss, cash flow hedge, reclassification tax	$ (276)	$ (276)

Accumulated Other Comprehensi_4

Accumulated Other Comprehensive Loss - Narrative (Details) - USD ($)	6 Months Ended	12 Months Ended
	Sep. 30, 2021	Mar. 31, 2021
Stockholders' Equity Note [Abstract]
Reclassification from accumulated other comprehensive loss into earnings	$ 0	$ 0

Earnings Per Share - Computatio

Earnings Per Share - Computation of Basis and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Numerator
Net income	$ 45,325	$ 44,589	$ 103,080	$ 88,295
Denominator
Denominator for basic earnings per share — weighted average shares outstanding (in shares)	50,232	50,330	50,186	50,297
Dilutive effect of nonvested restricted stock units and options issued to employees and directors (in shares)	559	331	545	375
Denominator for diluted earnings per share (in shares)	50,791	50,661	50,731	50,672
Earnings per Common Share:
Basic earnings per share (in USD per share)	$ 0.90	$ 0.89	$ 2.05	$ 1.76
Diluted earnings per share (in USD per share)	$ 0.89	$ 0.88	$ 2.03	$ 1.74

Earnings Per Share - Antidiluti

Earnings Per Share - Antidilutive Securities (Details) - shares shares in Millions	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Outstanding Stock Awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	0.4	0.6	0.4	0.6

Share-Based Compensation - Narr

Share-Based Compensation - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions	Aug. 03, 2021	May 03, 2021	May 31, 2014	Jun. 30, 2014	Sep. 30, 2021	Sep. 30, 2020	Jun. 23, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares per participant, 12 month period			1,000,000	2,500,000
Extension of plan term				10 years
Unrecognized compensation costs related to nonvested awards					$ 4
Unrecognized compensation costs related to nonvested awards, weighted average period for recognition					2 years 2 months 12 days
Shares available for issuance under the Plan (in shares)					2,500,000
Stock options granted (in shares)					234,200	249,900
Options exercised, aggregate intrinsic value					$ 1.8
Restricted Stock Units (RSUs) & Performance Stock Units (PSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation costs related to nonvested awards					$ 11.2
Unrecognized compensation costs related to nonvested awards, weighted average period for recognition					2 years
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share grants in period		77,345
Restricted Stock Units (RSUs) & Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share grants in period		73,108
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted (in shares)		222,660
Stock options granted, exercise price (in USD per share)		$ 44.33
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share grants in period		1,636			170,800	179,700
Restricted Stock Units (RSUs) | Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share grants in period	2,808
Long-term Equity Incentive Plan, 2005
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for grant			5,000,000
Number of additional shares authorized				1,800,000
Long-term Incentive Plan, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)							2,827,210
Number of new shares for future issuance under 2020 long-term incentive plans							2,000,000
Number of unissued shares reserved for 2020 long-term incentive plans							827,210

Share-Based Compensation - Stoc

Share-Based Compensation - Stock Based Compensation Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
Pre-tax share-based compensation costs charged against income	$ 3,219	$ 2,892	$ 5,097	$ 4,356
Income tax benefit recognized on compensation costs	369	451	512	563
Total fair value of options and RSUs vested during the period	937	1,015	7,943	6,796
Cash received from the exercise of stock options	503	69	2,707	1,285
Tax benefits realized from tax deductions resulting from RSU issuances and stock option exercises	$ 350	$ 4	$ 2,071	$ 948

Share-Based Compensation Restri

Share-Based Compensation Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) - $ / shares	May 03, 2021	Sep. 30, 2021	Sep. 30, 2020
Shares
Outstanding, beginning of period (in shares)		457,000	387,900
Granted (in shares)	1,636	170,800	179,700
Vested (in shares)		(162,300)	(100,200)
Forfeited (in shares)		(24,600)	(4,700)
Outstanding, end of period (in shares)		440,900	462,700
Vested, end of period (in shares)		152,300	150,400
Weighted Average Grant-Date Fair Value
Outstanding, beginning of period, weighted-average grant-date fair value (in USD per share)		$ 33.52	$ 33.11
Granted, weighted-average grant-date fair value (in USD per share)		45.32	40.22
Vested, weighted-average grant-date fair value (in USD per share)		32.99	42.94
Forfeited, weighted-average grant-date fair value (in USD per share)		30.54	56.11
Outstanding, end of period, weighted-average grant-date fair value (in USD per share)		38.45	33.51
Vested, end of period, weighted-average grant-date fair value (in USD per share)		$ 33.92	$ 31.98

Share-Based Compensation Stock

Share-Based Compensation Stock Option Valuation Assumptions (Details) - Stock Options - USD ($)	6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividends	$ 0	$ 0
Granted, weighted-average grant-date fair value (in USD per share)	$ 14.87	$ 12.91
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	31.10%	32.10%
Expected term in years	6 years	6 years
Risk-free rate	1.00%	0.50%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	31.90%	32.20%
Expected term in years	7 years	7 years
Risk-free rate	1.30%

Share-Based Compensation Stoc_2

Share-Based Compensation Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Shares
Outstanding, beginning of period (in shares)	1,114,900	1,020,200
Granted (in shares)	234,200	249,900
Exercised (in shares)	(87,600)	(62,800)
Forfeited (in shares)	(13,700)	0
Expired (in shares)	(8,500)	0
Outstanding, end of period (in shares)	1,239,300	1,207,300
Exercisable, end of period (in shares)	759,700	699,100
Weighted Average Exercise Price
Outstanding, beginning of period, weighted-average exercise price (in USD per share)	$ 37.92	$ 35.90
Granted, weighted-average exercise price (in USD per share)	44.74	39.98
Exercised, weighted-average exercise price (in USD per share)	30.91	20.46
Forfeited, weighted-average exercise price (in USD per share)	37.83	0
Expired, weighted-average exercise price (in USD per share)	56.63	0
Outstanding, end of period, weighted-average exercise price (in USD per share)	39.58	37.55
Exercisable, end of period, weighted-average exercise price (in USD per share)	$ 39.06	$ 39.39
Options, Additional Disclosures:
Outstanding, end of period, weighted-average remaining contractual term	6 years 8 months 12 days	7 years
Exercisable, end of period, weighted-average remaining contractual term	5 years 3 months 18 days	5 years 7 months 6 days
Outstanding, end of period, aggregate intrinsic value	$ 20,593	$ 5,032
Exercisable, end of period, aggregate intrinsic value	$ 13,060	$ 3,430

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Effective income tax rate	24.00%	14.10%	24.20%	19.80%
Tax credit carryforwards, foreign	$ 5.1		$ 5.1

Employee Retirement Plans - Exp

Employee Retirement Plans - Expected Return on Plan Assets (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
Interest cost	$ 278	$ 525	$ 556	$ 1,050
Expected return on assets	(290)	(647)	(580)	(1,294)
Net periodic benefit income	$ (12)	$ (122)	$ (24)	$ (244)

Employee Retirement Plans - Nar

Employee Retirement Plans - Narrative (Details) - USD ($)	6 Months Ended
	Sep. 30, 2021	Mar. 31, 2021
Pension Plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined benefit plan, benefit obligation		$ 52,100,000
Non-qualified Plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Employer contributions	$ 200,000
Expected employer contributions, remainder of fiscal year	200,000
Qualified Plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Expected employer contributions, remainder of fiscal year	$ 0

Concentrations of Risk (Details

Concentrations of Risk (Details) - manufacturer	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Concentration Risk [Line Items]
Number of third-party manufacturers	121	113	121	113
Sales | Customer Concentration Risk | Walmart
Concentration Risk [Line Items]
Concentration risk, percentage	22.70%	22.50%	21.20%	22.30%
Sales | Supplier Concentration Risk
Concentration Risk [Line Items]
Number of third-party manufacturers with long-term contracts			19	19
Top 5 brands | Sales | Product Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	41.30%	45.80%	43.30%	46.20%
Manufactures | Sales | Supplier Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage			68.10%	65.40%

Business Segments - Information

Business Segments - Information on Operating and Reportable Segments (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Segment Reporting Information, Profit (Loss):
Total revenues	$ 276,225	$ 237,422	$ 545,406	$ 466,816
Cost of sales	118,513	99,761	228,682	195,287
Gross profit	157,712	137,661	316,724	271,529
Advertising and marketing	40,730	38,341	80,169	66,091
Contribution margin	116,982	99,320	236,555	205,438
Other operating expenses	38,424	26,417	66,655	52,416
Operating income	78,558	72,903	169,900	153,022
North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	251,728	216,575	494,121	427,233
International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	24,497	20,847	51,285	39,583
Operating Segments | North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	251,728	216,575	494,121	427,233
Cost of sales	108,623	91,069	208,027	178,896
Gross profit	143,105	125,506	286,094	248,337
Advertising and marketing	36,493	34,014	71,723	58,694
Contribution margin	106,612	91,492	214,371	189,643
Operating Segments | International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	24,497	20,847	51,285	39,583
Cost of sales	9,890	8,692	20,655	16,391
Gross profit	14,607	12,155	30,630	23,192
Advertising and marketing	4,237	4,327	8,446	7,397
Contribution margin	10,370	7,828	22,184	15,795
Intersegment Eliminations | North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	$ 700	$ 600	$ 1,700	$ 1,600

Business Segments - Revenue (De

Business Segments - Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	$ 276,225	$ 237,422	$ 545,406	$ 466,816
Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	30,339	30,890	63,566	59,031
Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	28,028	17,882	46,920	35,222
Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	68,365	65,598	135,557	133,439
Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	46,605	38,097	99,175	73,852
Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	40,806	29,804	80,251	55,201
Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	33,204	28,711	65,293	57,030
Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	26,171	25,078	50,127	50,423
Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	2,707	1,362	4,517	2,618
North American OTC Healthcare
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	251,728	216,575	494,121	427,233
North American OTC Healthcare | Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	29,943	30,623	62,764	58,490
North American OTC Healthcare | Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	23,022	14,796	37,067	28,234
North American OTC Healthcare | Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	65,020	61,492	128,268	126,902
North American OTC Healthcare | Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	37,964	31,718	80,330	61,768
North American OTC Healthcare | Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	37,818	26,767	73,805	49,619
North American OTC Healthcare | Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	32,365	27,875	63,515	55,495
North American OTC Healthcare | Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	22,893	21,944	43,860	44,110
North American OTC Healthcare | Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	2,703	1,360	4,512	2,615
International OTC Healthcare
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	24,497	20,847	51,285	39,583
International OTC Healthcare | Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	396	267	802	541
International OTC Healthcare | Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	5,006	3,086	9,853	6,988
International OTC Healthcare | Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	3,345	4,106	7,289	6,537
International OTC Healthcare | Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	8,641	6,379	18,845	12,084
International OTC Healthcare | Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	2,988	3,037	6,446	5,582
International OTC Healthcare | Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	839	836	1,778	1,535
International OTC Healthcare | Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	3,278	3,134	6,267	6,313
International OTC Healthcare | Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	$ 4	$ 2	$ 5	$ 3

Business Segments Revenue by Ge

Business Segments Revenue by Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	$ 276,225	$ 237,422	$ 545,406	$ 466,816
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	236,151	203,289	462,818	402,635
Rest of world
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	$ 40,074	$ 34,133	$ 82,588	$ 64,181

Business Segments Goodwill and

Business Segments Goodwill and Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Mar. 31, 2021
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	$ 578,797	$ 578,079
Intangible assets
Indefinite-lived	2,481,590	2,281,988
Finite-lived, net	208,330	193,741
Intangible assets, net	2,689,920	2,475,729
Total	3,268,717	3,053,808
North American OTC Healthcare
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	548,401	546,643
Intangible assets
Indefinite-lived	2,399,717	2,195,617
Finite-lived, net	205,267	190,462
Intangible assets, net	2,604,984	2,386,079
Total	3,153,385	2,932,722
International OTC Healthcare
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	30,396	31,436
Intangible assets
Indefinite-lived	81,873	86,371
Finite-lived, net	3,063	3,279
Intangible assets, net	84,936	89,650
Total	$ 115,332	$ 121,086